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Introduction 
The concept of the metabolic syndrome has first been described as early as in the 
1920s [1]. Earlier described as the insulin resistance syndrome [2], syndrome X [3], 
or the deadly quartet [4], the metabolic syndrome is a constellation of metabolic 
disturbances that strongly enhances the risk of cardiovascular disease (CVD) and 
type 2 diabetes mellitus [5]. Together with the global epidemic of obesity and diabe-
tes, the incidence of the metabolic syndrome has increased strikingly during the 
past few decades [6]. In countries with westernized lifestyles, the prevalence has 
been estimated to exceed 20% and is expected to further increase during the next 
years [7]. In the Netherlands, the average proportion of the adult population having 
the metabolic syndrome has been estimated around 15%, and this number in-
creases with age [8, 9]. However, although it has for long been regarded as a dis-
ease of adults, its prevalence in children and teenagers is also rising at an alarming 
rate [10]. It may therefore be clear that there is an urgent need for timely recogni-
tion and treatment of the metabolic syndrome. 
Definition of the metabolic syndrome 
The metabolic syndrome is characterized by abnormalities in a wide variety of 
metabolic risk markers, including abdominal obesity, hypertension, atherogenic 
dyslipidemia, insulin resistance, and a prothrombotic and proinflammatory state. 
During the past decades, several clinical criteria for the diagnosis of the metabolic 
syndrome were developed. In 1998, the World Health Organisation (WHO) was the 
first to propose a set of criteria for diagnosing the metabolic syndrome, in an at-
tempt to achieve some agreement on definition [11]. Subsequent definitions were 
formulated by the European Group for the Study of Insulin Resistance (EGIR) [12], 
the National Cholesterol Education Program’s (NCEP) Adult Treatment Panel III (ATP 
III) [13] raised by the National Heart, Lung, and Blood Institute (NHLBI), and the In-
ternational Diabetes Federation (IDF) [14]. To date, the ATP III definition is the most 
widely used [15]. To diagnose the metabolic syndrome according to the ATP III crite-
ria, at least 3 of the following risk factors should be present: abdominal obesity, in-
creased triglycerides (TG), decreased high density lipoprotein (HDL) cholesterol, ele-
vated blood pressure, or increased fasting glucose (Table 1.1). 
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Table 1.1. NECP-ATP III clinical criteria for diagnosis of the metabolic syndrome. 
Risk factor Defining level 
Abdominal obesity, given as waist circumference > 102 cm (men) 
> 88 cm (women) 
Triglycerides ≥ 1.7 mmol/L 
HDL cholesterol < 1.03 mmol/L (men) 
< 1.30 mmol/L (women) 
Blood pressure ≥ 130 / ≥ 85 mm Hg 
Fasting glucose ≥ 6.1 mmol/L 
Pathophysiology of the metabolic syndrome 
The aetiology of the metabolic syndrome has not yet been established. However, it 
is clear that obesity, insulin resistance, inflammation and environmental factors, 
such as diet, are major players in its development. An overview of the pathophysi-
ology of the metabolic syndrome is presented in Figure 1.1. 
Obesity 
One major hypothesis to describe the pathophysiology of the metabolic syndrome, 
supported by the NHLBI, presumes obesity to be the primary underlying cause [13]. 
Obesity contributes to hypertension, dyslipidemia, inflammation and hyperglycae-
mia and is associated with CVD risk. Although obesity is not a requirement for hav-
ing the metabolic syndrome, the worldwide increase in obesity during the past two 
decades was accompanied by a rise in the incidence of the metabolic syndrome [6]. 
In this respect, abdominal fat is more important than total body fat, which is why 
waist circumference is one of the ATP III diagnostic criteria. Adipose tissue, in par-
ticular visceral adipose tissue, is now regarded as an endocrine organ, secreting 
numerous hormones and adipokines involved in lipid and glucose metabolism, regu-
lation of blood pressure, inflammatory processes and thrombotic function, including 
cytokines and plasminogen activator inhibitor-1 (PAI-1) [16]. Moreover, adipose tis-
sue releases free fatty acids (FFA), which are thought to be a main contributor to 
the pathogenesis of the metabolic syndrome [17, 18]. 
Insulin resistance 
Insulin is produced by the pancreas in response to elevated plasma glucose concen-
trations and stimulates glucose uptake in various tissues. In skeletal muscle and adi-
pose tissue, insulin stimulates glucose uptake by translocation of the GLUT4 glucose 
transporter to the cell surface. In skeletal muscle and liver, insulin stimulates the 
synthesis of glycogen from glucose and inhibits its degradation (glycogenolysis). In 
the liver, insulin suppresses the production of glucose (gluconeogenesis), preventing 
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rises in blood glucose levels. In adipose tissue, insulin inhibits fat breakdown (lipoly-
sis) and stimulates glucose uptake. The net effect of all these actions is an increase 
in glucose uptake, a decrease in circulating glucose, and an increase in the conver-
sion of glucose into storage molecules (glycogen or fat). In insulin resistance, adi-
pose, muscle and liver cells do not respond appropriately to insulin. The resulting 
rises in blood glucose levels, and the related increases in insulin concentrations, 
may subsequently lead to pathologies. 
 Identifying a unique role for insulin resistance in the pathophysiology of the 
metabolic syndrome is complicated by the fact that it is linked to obesity. Insulin re-
sistance generally rises with increasing body fat content, although insulin sensitivity 
varies widely at any given level of body fat and insulin resistance also occurs at BMI 
<25 kg/m
2
 [19]. So, since obesity and insulin resistance are tightly intertwined, dis-
sociation of these two factors in patients with the metabolic syndrome is difficult. 
An increased flux of FFA to the liver, muscles and pancreas, overloading these tis-
sues with lipid, may enhance insulin resistance [18, 20]. Circulating fatty acids are 
mainly derived from adipose tissue TG stores, released through the action of the 
enzyme hormone sensitive lipase. An increased flux of FFA to the liver increases the 
hepatic fat content, which may result in the development of fatty liver and hepatic 
insulin resistance [21]. Insulin resistance in the liver leads to hepatic overproduction 
of glucose and a reduced inhibition of glucose production by insulin. Also, insulin 
suppression of glycogenolysis is reduced, all contributing to elevated plasma glucose 
concentrations. Further, the secretion of very low density lipoproteins (VLDL) from 
the liver is enhanced. In muscle, excess FFA reduces insulin sensitivity by inhibiting 
insulin-mediated glucose uptake through glucose transporters [22].  
Atherogenic dyslipidemia 
Lipids are transported in the body by lipoproteins. In the intestine, TG and choles-
terol are incorporated into chylomicrons, which are transported via the lymph sys-
tem into the circulation. The enzyme lipoprotein lipase (LPL) hydrolyzes the TG into 
FFA, which are used in muscle or stored in adipose tissue, thereby reducing the chy-
lomicron size. The chylomicron remnant is transported to the liver, where it is taken 
up and degraded. In the liver, TG are synthesized from FFA and, when exogenous 
cholesterol supply is insufficient, endogenous cholesterol is synthesized from acetyl-
coenzyme A. These TG and cholesterol molecules are incorporated into VLDL parti-
cles for transport from the liver to the peripheral tissues. Like chylomicrons, VLDL 
particles release their TG content in the form of FFA to the tissues through the ac-
tion of LPL. As its density increases, the particle becomes an intermediate density 
lipoprotein (IDL). IDL further loses its TG, as well as its apolipoproteins (apo), except 
for apoB100. The remaining particle is thus composed of mainly cholesterol esters 
and apoB100 proteins and is now called LDL. LDL delivers cholesterol to the periph-
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eral tissues and the liver and is subsequently taken up and degraded by the liver. 
HDL is the smallest lipoprotein and has the highest density, because of the relatively 
high content of protein in the particle, predominantly apoA-I and apoA-II. HDL is the 
lipoprotein responsible for the transport of cholesterol from the tissues back to the 
liver and HDL cholesterol is therefore regarded as the ‘good’ cholesterol. HDL is syn-
thesized in the liver and picks up cholesterol on its way through the circulation. 
 The key features of atherogenic dyslipidemia in the metabolic syndrome are 
elevated plasma TG, reduced HDL cholesterol, and increased small dense LDL parti-
cles [13]. Both insulin resistance and abdominal obesity are associated with athero-
genic dyslipidemia and an increased flux of FFA to the liver is probably the major 
contributor [23]. Under normal conditions, insulin inhibits the production of apoB, 
the major lipoprotein on VLDL particles, and the secretion of VLDL into the circula-
tion. In the insulin resistant state, an increased flux of FFA to the liver increases he-
patic TG synthesis, apoB production, and TG secretion in the form of VLDL [24]. In 
this way, VLDL output by the liver is enhanced and plasma concentrations of TG rise 
[25]. Further, the activity of LPL, the rate-limiting and major mediator of VLDL clear-
ance, is regulated by insulin. In case of insulin resistance, VLDL clearance is there-
fore reduced, also contributing to elevated levels of TG in the circulation [26]. 
 The rise in VLDL is usually associated with a decrease in HDL-C and an increase 
in LDL density. The TG in VLDL are transferred to HDL by the cholesterol ester trans-
port protein (CETP) in exchange for cholesterol esters, resulting in TG-enriched HDL 
and cholesterol ester-enriched VLDL particles. The TG-enriched HDL is a better sub-
strate for hepatic lipase, and is therefore rapidly cleared from the circulation, leav-
ing fewer HDL particles available for cholesterol transport from the tissues to the 
liver. Similarly, small dense LDL particles are formed. CETP facilitates the transfer of 
TG from large VLDL to LDL in exchange for cholesterol esters, after which hepatic li-
pase increases lipolysis of TG-rich LDL, resulting in the formation of small dense LDL 
particles [24]. Small dense LDL might be more atherogenic than large buoyant LDL, 
because it is more toxic to the endothelium, it passes the endothelial basement 
membrane more easily, it is more susceptible to oxidation, and/or it is more selec-
tively bound to scavenger receptors on macrophages [27, 28].  
Low-grade chronic inflammation 
Although inflammatory markers are currently not included in the ATP III or WHO di-
agnostic criteria for the metabolic syndrome, chronic inflammation is receiving large 
attention as a metabolic syndrome component and cardiovascular risk factor. In-
flammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumour 
necrosis factor-α (TNF-α), and fibrinogen, among others, have been linked to the 
metabolic syndrome [29]. An enlarged adipose tissue mass is responsible for the in-
creased production of cytokines such as TNF-α and IL-6, which may in turn stimulate 
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the production of CRP by the liver. Although many inflammatory markers have been 
associated with CVD risk, CRP concentrations are particularly predictive of CVD risk 
[30]. These inflammatory proteins are now also thought to play a major role in the 
development of insulin resistance in muscle and liver [31]. Cytokines also stimulate 
the production of fibrinogen and PAI-1 by the liver, resulting in a prothrombotic 
state [29].  
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Figure 1.1. Pathophysiology of the metabolic syndrome. 
Complications of the metabolic syndrome 
It seems self-evident that a condition characterized by multiple risk factors will carry 
a greater risk for adverse clinical outcomes than will a single risk factor. Although 
ATP III identified CVD as the primary clinical outcome of the metabolic syndrome, 
people with this syndrome may also have insulin resistance, which strongly predis-
poses to the development type 2 diabetes mellitus. When diabetes becomes clini-
cally apparent, CVD risk is even more enhanced. Beyond CVD and type 2 diabetes, 
patients with the metabolic syndrome are also susceptible to other conditions, in-
cluding polycystic ovary syndrome, fatty liver, cholesterol gallstones, asthma, sleep 
disturbances, and some forms of cancer [13].  
 The term CVD refers to the class of diseases that involve the heart and blood 
vessels, such as myocardial infarction, diseases of the heart valves or muscle, heart 
failure, and stroke. However, the term CVD is usually used to describe atherosclero-
sis: a slow, complex, chronic disease, which is the primary cause of CVD [32]. The 
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process of atherosclerosis is a continuum, already starting at an early age, in which a 
plaque is formed in the vessel wall. Endothelial dysfunction seems to be the process 
initiating the development of atherosclerosis. High concentrations of glucose, FFA, 
LDL cholesterol, and inflammatory cytokines, among others, are factors that can 
damage the endothelial layer of the blood vessel, making it more permeable for 
atherogenic LDL particles. Once migrated into the underlying intima layer, the ac-
cumulating LDL particles can undergo oxidation. Oxidized LDL stimulates the expres-
sion of adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1), on the endothelial cells, attracting 
monocytes to the site of damage. The monocytes migrate into the intima layer, 
where they transform into macrophages. These macrophages are able to take up 
large amounts of oxidized LDL through their scavenger receptors and become lipid-
filled foam cells. Surrounding smooth muscle cells and endothelial cells then start to 
secrete cytokines and growth factors, promoting smooth muscle cells to proliferate 
and migrate through the endothelium. The migrated smooth muscle cells then be-
gin to synthesize extracellular matrix components, particularly collagen. Eventually, 
the lipid-filled foam cells are covered by a fibrous cap, consisting of collagen-rich fi-
brous tissue, smooth muscle cells, macrophages and thrombocytes. This is called 
the mature atherosclerotic plaque. The plaque protrudes into the arterial lumen 
and can finally obstruct the artery. Moreover, rupture of the plaque causes the for-
mation of a thrombus, which can block a coronary or cerebral artery and lead to a 
myocardial or cerebrovascular infarction.  
Treatment of the metabolic syndrome 
Due to its multifaceted character, no straightforward approach exists to treat the 
metabolic syndrome. The primary goal of clinical management of the metabolic 
syndrome is to reduce the risk for CVD and type 2 diabetes. Lifestyle modification, 
focusing on weight reduction and exercise, is an important part of the treatment 
regimen [33, 34]. Modest weight reduction through diet and exercise will result in 
an improved serum lipoprotein profile, reduced blood pressure, improved glucose 
homeostasis, and a reduced inflammatory state. A regular exercise program, includ-
ing a minimum of 30 minutes of moderate physical exercise on most days of the 
week, is advised. In addition, a diet rich in vegetables, fruits, whole grains, fish, and 
low-fat dairy products is recommended to improve cardiovascular health. Patients 
should reduce the intake of saturated fats, trans fats, cholesterol, and simple sug-
ars. Moreover, nutrient-dense, low-energy foods should replace low-nutrient, high-
calorie foods. Besides these dietary principles, there might be additional food prod-
ucts or food compounds that have a beneficial impact on the metabolic syndrome 
or its components. In this respect, dairy products are one group of food products 
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that are thought to have positive effects and that deserve special attention. The ef-
fects of dairy product consumption on the metabolic syndrome are discussed in 
chapter 2. Finally, drug therapy might be appropriate to reduce the risk of develop-
ing CVD or type 2 diabetes mellitus. However, it should be noticed that no single 
drug could treat all risk factors belonging to the metabolic syndrome. 
Outline of the thesis 
This thesis describes the results of human intervention studies and in vitro experi-
ments addressing the effects of dairy products or its constituents on several meta-
bolic disturbances associated with the metabolic syndrome. In chapter 2, an over-
view of the literature available on the effects of low-fat dairy consumption on the 
metabolic syndrome is given. The human intervention study described in chapter 3 
was designed to investigate the effects of low-fat dairy consumption on metabolic 
syndrome components in overweight and obese subjects. In chapter 4, the effects 
of low-fat dairy consumption on a range of markers of low-grade chronic inflamma-
tion in the same population are described. Further, we studied the effects of dairy 
and dairy constituents on postprandial responses in overweight and obese men. The 
results of this trial are presented in chapter 5. In the in vitro experiments described 
in chapter 6, we studied the effects of the amino acids glutamine, leucine and 
proline on inflammatory cytokine production and insulin signalling in a liver cell 
model. Finally, chapter 7 discusses the main findings and conclusions based on the 
studies described in this thesis.  
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ABSTRACT 
 
The metabolic syndrome is an important risk factor for type 2 diabetes mellitus 
and cardiovascular disease. Epidemiological studies have now suggested pro-
tective effects of dairy consumption on the development of this syndrome. 
Here we review the physiological effects and possible mechanisms involved of 
three main dairy constituents (calcium, protein, fat) on important components 
of the metabolic syndrome. Calcium supplements improve the serum lipopro-
tein profile, particularly by decreasing serum total and LDL-cholesterol concen-
trations. They also lower systolic and diastolic blood pressure. Insufficient evi-
dence exists for a significant role of calcium supplements or dairy in body 
weight management. Effects of calcium may be related to intestinal binding to 
fatty acids or bile acids, or to changes in intracellular calcium metabolism by 
suppressing calciotropic hormones. Dietary proteins may increase satiety on 
both the short and longer term, which may result in a reduced energy intake. 
They have also been reported to improve the serum lipoprotein profile as 
compared to carbohydrates. Dairy proteins are precursors of ACE-inhibitory 
peptides, which may lower blood pressure. Such effects, however, have incon-
sistently been reported in human studies. Finally, conjugated linoleic acid 
(CLA), which effectively lowers body weight in animals, has no such effect in 
humans in the quantities provided by dairy products. To reduce the intake of 
saturated fatty acids, the consumption of low-fat instead of high-fat dairy is 
recommended. In conclusion, more research is warranted to better under-
stand the physiological effects and the mechanisms involved of dairy products 
in the prevention and treatment of the metabolic syndrome. 
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Introduction 
The metabolic syndrome dramatically enhances the risk to develop cardiovascular 
disease and type 2 diabetes mellitus. It consists of a combination of different meta-
bolic abnormalities, such as abdominal obesity, atherogenic dyslipidemia, elevated 
blood pressure, insulin resistance, glucose intolerance, impaired endothelial and 
haemostatic function, and a low-grade inflammatory state [13]. The prevalence of 
the metabolic syndrome among the adult population exceeds 20% in many Western 
societies and is expected to increase in the very near future [35]. Without doubt, 
this will have important economic and health consequences, and unfortunately no 
straightforward approach exists to prevent or treat the metabolic syndrome.  
 However, it is well established that both energy restriction and dietary composi-
tion play an important role in this respect. More specifically, several studies have 
suggested that dairy food products have a positive impact on the prevention of the 
metabolic syndrome. The aim of the present review is now to briefly summarize 
findings from epidemiological studies on the relationship between dairy consump-
tion and the metabolic syndrome and to discuss the results from intervention stud-
ies on the effects of dairy and dairy constituents on features of this syndrome. In 
addition, attention is paid to underlying mechanisms. We hereby focussed on stud-
ies carried out during the last decade.  
Dairy consumption and the metabolic syndrome 
A number of epidemiological studies have investigated the relationship between 
dairy consumption and the prevalence or incidence of the metabolic syndrome. In 
2000, Mennen et al. [36] showed in a cross-sectional study that consumption of 
dairy products was inversely related with the prevalence of the metabolic syndrome 
in men (aged 30-64 y), but not in women. Men who consumed more than 1 portion 
of dairy products per day had a 40% lower prevalence of the metabolic syndrome 
compared with men who did not consume dairy products at all. In another cross-
sectional study, Azadbakht et al. [37] demonstrated an inverse association between 
dairy consumption and the metabolic syndrome in healthy Tehranian subjects aged 
18-74 y. In the group with the highest dairy intake (≥3.1 servings/d of milk, yogurt, 
cheese and milk-based desserts) the prevalence of the metabolic syndrome was 7% 
lower compared with the group with the lowest dairy intake (<1.7 servings/d). In 
addition, Elwood and colleagues [38] have recently found a negative relationship 
between milk and dairy intake and the prevalence of the metabolic syndrome in a 
study among 45-49 y old men. Similar results were observed by Ruidavets et al. [39], 
who showed in a cross-sectional sample of 45-64 y old men that intake of dairy 
products (milk and cheese) was negatively related to the prevalence of the 
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metabolic syndrome. However, a cross-sectional study by Beydoun et al. [40] among 
4519 US adults showed that the various dairy products may have different 
associations with the metabolic syndrome. While cheese consumption showed a 
positive relationship with the prevalence of the metabolic syndrome, the intake of 
yogurt resulted in a negative relationship. In contrast, in an elderly Dutch 
population Snijder et al. [41] did not find associations between dairy consumption 
and the metabolic syndrome. Also after differentiation between low-fat and high-fat 
dairy products, no significant associations were found. In the same population, 
baseline dairy consumption was also not related to the risk to develop the 
metabolic syndrome in the next 6.4 years [42]. However, in the prospective 
Coronary Artery Risk Development in Young Adults (CARDIA) study [43] among 
more than 3000 young (aged 18-30 y) men and women, it was found that in 
overweight subjects dairy consumption was inversely associated with the 
development of all components of the metabolic syndrome over the next 10 years. 
In another prospective study by Lutsey et al. [44], dairy consumption was inversely 
associated with the incidence of the metabolic syndrome in more than 9500 US 
subjects (45-64 y) after 9 years of follow-up. 
 Though not consistent, the majority of epidemiological studies do suggest that 
dairy products may play a role in the prevention and development of the metabolic 
syndrome. However, which of the components from dairy products may be respon-
sible for these possible positive effects is not clear, as are the mechanisms behind 
these effects. However, several intervention studies have been performed on the 
effects of single nutrients from dairy products on the different features of the 
metabolic syndrome. In this respect, much attention has been paid to calcium, pro-
tein, and fat. 
Calcium 
Dairy products are an important source of calcium [45, 46]. High intakes of dietary 
calcium may be associated with a lower prevalence of the various risk markers be-
longing to the metabolic syndrome, as indicated by epidemiological studies [47, 48]. 
A number of intervention studies also showed beneficial effects of calcium on fea-
tures of the metabolic syndrome. 
Effects of calcium on the serum lipid profile 
Calcium may affect the serum lipoprotein profile. Calcium provided as a food 
supplement has been found to increase serum HDL-cholesterol concentrations [49], 
and to decrease serum total cholesterol[50] and LDL-cholesterol concentrations 
[51]. As a consequence, calcium intake also improved the HDL:LDL cholesterol ratio, 
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which may be even a better marker to predict cardiovascular risk than LDL or HDL 
per se. Reid et al. [49] found beneficial effects on circulating lipid levels after 12 
months of calcium supplementation. Two hundred and twenty-three 
postmenopausal women were given 1 g of calcium daily as calcium citrate or 
placebo. HDL cholesterol and the HDL:LDL cholesterol ratio significantly increased 
by 0.13 mmol/L and 0.06, respectively. No statistically significant decreases in total 
cholesterol (-0.18 mmol/L) and LDL cholesterol (-0.29 mmol/L) were observed. In 
the cross-over study of Ditscheid et al. [50], thirty-one healthy adults received 1 g of 
calcium daily, supplied as pentacalcium hydroxy-triphosphate in bread, or non-
supplemented bread for 4 weeks. A significant decrease in total cholesterol (-0.24 
mmol/L), and non-significant decreases in LDL cholesterol (-0.14 mmol/L) and the 
LDL:HDL cholesterol ratio (-0.85) were found. Shahkhalili et al. [51] observed 
significantly decreased serum LDL cholesterol concentrations (-0.32 mmol/L) and a 
non-significant decrease in total cholesterol (-0.34 mmol/L). In this study, ten 
healthy men received calcium supplemented chocolate (900 mg calcium daily) or 
non-supplemented chocolate for 2 weeks in a crossover design. On the contrary, 
Bostick et al. [52] did not find significant effects of calcium supplementation on the 
serum lipoprotein profile in 193 men and women aged 30-74 y. Subjects received 1 
or 2 g of calcium daily, given as calcium carbonate, for 4 months. No statistically 
significant differences in serum total cholesterol and HDL cholesterol concentrations 
were found between the calcium and placebo groups. A summary of human 
intervention studies on the effects of calcium supplements on the serum lipid 
profile is given in Table 2.1. 
Possible mechanisms underlying the effects of calcium on the serum lipid profile 
Two potential mechanisms have been proposed by which calcium might affect lipo-
protein metabolism. One mechanism is the inhibition of fat absorption in the intes-
tine (Figure 2.1). Calcium interacts in particular with saturated fatty acids to form 
calcium-fatty acid soaps. The formation of these insoluble complexes increases fecal 
fat excretion. Evidence for this interaction comes from a number of human studies 
[51, 53-55]. More recently, however, Boon and colleagues only observed a tendency 
towards an increased fecal fat excretion on high calcium (1200 or 2500 versus 400 
mg) diets [56]. In support of a decreased fat absorption, Lorenzen et al. [57] have 
shown that calcium from dairy (milk and low-fat yogurt), in contrast to supplemen-
tary calcium, diminished the triacylglycerol content of chylomicrons postprandially. 
This suggests either an increase in chylomicron clearance, or a decrease in fat ab-
sorption. As there is no evidence in the literature suggesting that calcium interferes 
with chylomicron clearance, effects on fat absorption are very likely. However, the 
reason for the difference between the effects of dairy and supplemental calcium is 
not clear. The authors suggested that other properties of dairy may be responsible 
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for the different effects, such as the chemical form of calcium (calcium phosphate in 
dairy vs. calcium carbonate in supplements) or the synergistic action of other dairy 
components.  
 
Table 2.1 Overview of intervention studies on the effects of dairy and calcium supplementation on serum 
lipid profile, blood pressure and glucose metabolism. 
MetS com-
ponent 
Subjects Design Additional calcium 
intake (mg/day) + 
source 
Control Effects Authors 
Lipid profile 223 elderly 
women 
Randomized,  
1 year 
1000  
(calcium citrate) 
Placebo TC 
LDL-C 
HDL-C 
HDL/LDL 
TG 
-0.18 mmol/L 
-0.29 mmol/L 
+0.13 mmol/L* 
+0.06* 
-0.02 mmol/L 
Reid  
2002 [49] 
Lipid profile 31 healthy 
adults 
Cross-over, 
double-blind, 
2x4 wk 
1000 (calcium 
phosphate in 
bread) 
Non-supplemented 
bread 
TC 
LDL-C 
LDL/HDL 
-0.24 mmol/L* 
-0.14 mmol/L  
-0.85 
Ditscheid 
2005 [50] 
Lipid profile 10 healthy 
men 
Randomized, 
double-blind, 
cross-over,  
2x2 wk 
900  
(supplemented 
chocolate) 
Non-supplemented 
chocolate 
TC 
LDL-C 
-0.34 mmol/L  
-0.32 mmol/L* 
Shahkhalili 
2001 [51] 
Lipid profile 193 healthy 
adults 
Randomized, 
double blind,  
4 months 
1000 or 2000 (cal-
cium carbonate) 
Placebo TC 
HDL-C 
-0.07 mmol/L 
+0.01 mmol/L 
Bostick  
2000 [52] 
Blood pres-
sure 
34 obese 
adults 
Randomized,  
24 wk 
700  
(dairy) 
Low-calcium,  
low-dairy diet 
SBP 
DBP 
-6.99 mm Hg* 
-4.37 mm Hg* 
Zemel  
2005 [58] 
 
Blood pres-
sure 
 
459 healthy 
adults 
Randomized,  
8 wk 
820 (dairy in diet 
rich in fruits and 
vegetables) 
Diet rich in fruits 
and vegetables 
SBP 
DBP 
-2.7 mm Hg* 
-1.9 mm Hg* 
Appel  
1997 [59] 
Blood pres-
sure 
 
34 obese 
adults 
Randomized,  
12 wk 
600  
(dairy in energy 
deficit diet) 
Low-calcium, en-
ergy deficit diet 
SBP 
DBP 
-2.59 mm Hg  
-4.37 mm Hg* 
Zemel  
2005 [60] 
Blood pres-
sure 
193 healthy 
adults 
Randomized, 
double blind,  
6 months 
1000 or 2000 (cal-
cium carbonate) 
Placebo SBP 
DBP 
-0.8 mm Hg  
-0.4 mm Hg 
Bostick  
2000 [52] 
Glucose 
metabolism 
 
34 obese 
adults 
Randomized,  
24 wk 
700  
(dairy) 
Low-calcium,  
low-dairy diet 
Fasting 
insulin  
-19.7 pM* Zemel  
2005 [58] 
Glucose 
metabolism 
32 obese 
adults 
Randomized,  
24 wk 
1200-1300  
(dairy in energy 
deficit diet) 
Low-calcium,  
low dairy energy 
deficit diet 
Glucose AUC ↓* 
Fasting insulin ↓* 
Zemel  
2004 [61] 
TC, Total Cholesterol; LDL-C, Low Density Lipoprotein Cholesterol; HDL-C, High Density Lipoprotein Cholesterol; TG, 
Triglycerides; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; AUC, Area Under the Curve. *P<0.05  
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Saturated fatty acids are known to increase total and LDL cholesterol, most likely by 
suppressing LDL-receptor activity [62]. The reduced absorption of saturated fatty ac-
ids may, at least in part, contribute to the LDL cholesterol-lowering effects of cal-
cium. Some studies have suggested that this mechanism may be less effective under 
high-protein conditions, because protein would increase the intestinal absorption of 
calcium [55, 63]. Whether or not this decreases the amount of calcium that is avail-
able for binding to fatty acids has, however, not been investigated. In fact, calcium 
is only partially absorbed and it may be speculated that the calcium content of high 
dairy diets is high enough to leave sufficient amounts of calcium in the gastro-
intestinal tract for binding to fatty acids. Another possible mechanism is that cal-
cium binds to bile acids (Figure 2.1). Indeed, in some human studies, calcium in-
creased the fecal excretion of bile acids [50, 51, 64]. In this way, reabsorption of bile 
acids into the enterohepatic circulation is inhibited, leading to an increased conver-
sion of cholesterol to bile acids in the liver and ultimately to decreased LDL choles-
terol levels.  
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Figure 2.1. One of the proposed mechanisms of action of dietary calcium. Calcium binds to saturated 
fatty acids (SFA) or bile acids (BA) in the intestine, inhibiting their absorption. SFA raise LDL cholesterol, 
probably by decreasing LDL receptor activity. Reduced absorption of SFA can therefore lower serum LDL 
cholesterol. In the liver, cholesterol is converted into BA. Lowering the absorption of BA in the intestine 
will therefore lead to an increased conversion of cholesterol and reduced serum LDL cholesterol levels. 
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Effects of calcium and dairy on body weight and fat mass 
Calcium may exert its effects on the metabolic syndrome by mediating body weight 
and fat mass. Observational as well as intervention studies suggest that high calcium 
intakes are associated with lower body weight and fat mass. Zemel and colleagues 
were among the first to report beneficial effects of calcium on body weight and fat 
mass. Furthermore, they have proposed that calcium from dairy sources exerts lar-
ger effects calcium from non-dairy sources. In a six-month trial [61], thirty-two 
obese subjects were maintained on energy deficit (-500 kJ/day) diets and random-
ized to control (zero to one servings of dairy products/day supplemented with pla-
cebo, providing 400-500 mg calcium/day), high calcium (control diet supplemented 
with 800 mg calcium/day as calcium carbonate), or high dairy (three servings/day 
supplemented with placebo, providing 1200-1300 mg of calcium/day) diets. Both 
weight loss and fat loss were higher on the high calcium diet than on the control 
diet, but even higher on the high dairy diet. Additionally, the largest percentage of 
fat from the trunk was lost on the high dairy diet, shifting the distribution of body 
fat loss to a more favourable pattern. Thus, dairy products exerted a substantially 
larger effect on both fat loss and fat distribution compared with an equivalent 
amount of supplemental calcium. This has been attributed to additional bioactive 
compounds in dairy, that may act synergistically with calcium to modulate body 
weight and fat mass [65]. Although the macronutrient composition of the diets was 
similar and the diets only differed in calcium content, the observed effects might 
partly be due to differences in protein source, for example. The augmentation of 
weight loss by dairy products was also observed in another study, in which an en-
ergy deficit yogurt diet (1100 mg Ca) was compared to an energy deficit control 
(400-500 mg Ca) diet [60]. While macronutrients were held constant and only cal-
cium contents differed, it cannot be concluded whether the effects are due to cal-
cium alone or also to other bioactive components in dairy. 
 Despite these positive results [60, 61], many other studies did not provide evi-
dence for weight or body fat reducing effects of calcium. Recently, Lanou and Bar-
nard [66] thoroughly reviewed forty-nine randomized controlled trials on the effects 
of dairy and calcium intake, with or without energy restriction, on body weight and 
adiposity. Of seventeen studies on dairy intake, fifteen showed no effect on body 
weight, while two reported weight gain. Nineteen trials used calcium supplements 
and found no effect on weight, while one study showed weight loss and one study 
found a lower rate of weight gain on calcium treatment. They identified six trials us-
ing dairy products in combination with reduced energy intake, of which three re-
ported no effects and three showed body weight loss. Of the five studies on calcium 
supplementation combined with energy restriction, four found no effect and one 
study observed weight loss. The authors therefore concluded that the majority of 
the current evidence from clinical trials does not support the hypothesis that cal-
cium or dairy consumption promotes weight or fat loss. 
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There is no clear explanation for the discrepancy between the positive results from 
the studies by Zemel [60, 61] and the large number of studies reporting no weight 
reducing effects of calcium and dairy consumption. It has been proposed that 
effects of calcium on body weight are only present in populations with low habitual 
intakes, and that at calcium consumption above 800 mg per day, no additive 
beneficial effects of increasing dietary calcium will occur [67]. However, Lanou and 
Barnard [66] also included trials among populations with suboptimal calcium 
intakes, which does not support this threshold hypothesis. It might also be 
speculated that dairy products and calcium supplements reduce body weight and 
fat mass only when part of an energy-restricted diet. This reasoning is, however, 
also not supported by the majority of studies [66]. 
Possible mechanisms underlying the effects of calcium on body weight and fat 
mass 
For the effects of calcium on body weight and body composition, the ability of cal-
cium to bind fatty acids and thereby inhibiting fat absorption, as discussed above, is 
proposed as one possible mechanism of action. Another way by which calcium 
might affect body composition, is by regulating intracellular calcium levels, as hy-
pothesized by Zemel et al. (Figure 2.2) [65]. Intracellular calcium levels are regu-
lated by calciotropic hormones, such as parathyroid hormone (PTH) and 1,25-
hydroxyvitamin D3 (calcitriol). High dietary calcium now depresses the levels of cal-
citriol, thereby decreasing intracellular calcium. This results in a stimulation of 
lipolysis. Additionally, low intracellular calcium inhibits the expression of fatty acid 
synthase (FAS), which is a key enzyme in de novo lipogenesis [65, 68]. Therefore, 
calcium intake may directly affect storage and breakdown of fat in adipose tissue. 
This mechanism has been demonstrated in human adipocytes in vitro, in which cal-
citriol increased intracellular calcium concentrations and inhibited lipolysis. Addi-
tionally, in transgenic mice, a high calcium diet reduced lipogenesis and stimulated 
lipolysis, resulting in reductions in body weight and adipose tissue mass [69]. How-
ever, this concept has not yet been shown in humans. In fact, in a series of trials 
performed by Boon and colleagues, the various steps of the Zemel hypothesis could 
not be confirmed. Although high calcium/high dairy intake did affect calcitriol me-
tabolism [70], and although changes in intracellular calcium did change lipolysis 
[71], changes in serum calcitriol did not alter fat metabolism in vivo [70].  
Effects of calcium on blood pressure 
Epidemiological as well as intervention studies have shown an inverse relationship 
between calcium intake and blood pressure [72, 73]. Several potential mechanisms 
may explain the positive effect of calcium on blood pressure, including reduced 
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membrane permeability to monovalent and divalent cations, reduced intracellular 
calcium levels, decreased concentrations of calcium-regulating hormones, reduced 
sympathetic nervous system activity, and altered metabolism of other electrolytes 
e.g. increased sodium excretion [74]. Again, the effect of calcium might be mediated 
by suppression of the hormone calcitriol. Suppression of this hormone could lower 
intracellular calcium levels in vascular smooth muscle cells, thereby reducing pe-
ripheral resistance and blood pressure [75]. Although it has been shown that calcit-
riol increases intracellular calcium in arteries of rats [76], and that an association ex-
ists between calcitriol and blood pressure in normotensive men [77], this hypothe-
sized mechanism has not yet been demonstrated in humans. A summary of human 
intervention studies on the effects of dairy and calcium supplements on blood pres-
sure is given in Table 2.1. 
 
↓ FAS 
transcription
↑ Dietary calcium
↓ 1,25-dihydroxy
Vitamin D3
Ca2+
↓ [Ca2+]i
↓ FAS
↓ de novo
lipogenesis
↑ lipolysis
 
Figure 2.2. Hypothesized mechanism of stimulation of lipolysis and inhibition of lipogenesis by dietary 
calcium. Increased dietary calcium intake lowers the level of the hormone 1,25-dihydroxy vitamin D3, 
thereby lowering the uptake of Ca
2+
 into the cell. Decreased levels of intracellular calcium stimulate 
lipolysis and decrease the transcription of fatty acid synthase (FAS), resulting in inhibition of lipogenesis. 
Effects of calcium on glucose metabolism 
Finally, one study showed a significant decrease in insulin levels in subjects consum-
ing a high dairy diet compared with subjects on a low dairy diet [58]. Thirty-four 
obese African-American adults were maintained on a low calcium (500 mg/day)/low 
dairy (<1 serving/day) or a high dairy (1200 mg calcium/day  including 3 servings of 
dairy) diet for 24 weeks. Circulating insulin decreased by 19.7 pM in subjects on the 
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high dairy diet compared with the low dairy diet (P<0.05). Although no differences 
in body weight were observed, subjects on the high dairy diet showed a decrease in 
body fat and an increase in lean mass, which might be related to the improved insu-
lin sensitivity. Another report from this laboratory showed similar results in thirty-
two obese adults [61]. Fasting glucose levels were unaffected by diet, but a 27% de-
crease in the area under the glucose curve and a 44% decrease in fasting plasma in-
sulin levels was observed on a high dairy diet, while these were unaffected on the 
low dairy diet. However, in this study it was not possible to discern whether these 
are direct effects of the high dairy diet, or secondary effects of the greater weight 
and fat loss found on this diet. Although in both studies the diets only differed in 
calcium content, it cannot be excluded that differences in the source of protein, for 
example, could have influenced the observed effects of dairy product consumption. 
Table 2.1 shows an overview of these studies of dairy on glucose metabolism. 
Conclusion 
Calcium supplements improve the serum lipid profile, most likely by decreasing to-
tal and LDL-cholesterol, thereby improving the HDL:LDL cholesterol ratio. Calcium 
and dairy also reduce blood pressure. While some studies have reported positive ef-
fects of dairy and calcium on body weight and body composition, the majority of 
trials do not support these findings. Calcium may exert its effects by intestinal bind-
ing to fatty acids and bile acids, or by depressing calciotropic hormones and chang-
ing intracellular calcium metabolism, although the evidence for the latter mecha-
nism is limited.  
Dairy protein 
Dairy products are an important source of protein. Nowadays, more and more at-
tention is paid to the role of protein in metabolic diseases.  
Effects of protein on the serum lipid profile and body weight regulation 
Recent evidence suggests that protein added to the diet at the expense of carbohy-
drates has favourable effects on serum lipoprotein profiles. Krauss et al. found a 
slight increase in both LDL and HDL cholesterol, but a decrease in the total:HDL cho-
lesterol ratio by proteins replacing carbohydrates [78]. In general, other studies also 
reported a decrease in the ratio of total:HDL cholesterol on high protein diets [79]. 
However, in the OmniHeart trial, a high protein diet decreased serum total choles-
terol, LDL cholesterol, HDL cholesterol, and triacylglycerol concentrations [80]. 
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Another interesting property of protein is its role in body weight regulation, which 
consists of different aspects. First, protein increases satiety, which may result in a 
decreased energy intake. On the short term, i.e. after an acute meal, consumption 
of high protein meals (60 to 81% of energy from protein) resulted in higher satiety 
compared with low or moderate protein meals [81-84] and a reduced energy intake 
[82, 83, 85]. Also in the longer term, high protein diets in studies lasting up to 4 days 
caused a continuously higher satiety throughout the day [86, 87]. In this respect, the 
effects of high protein diets do not seem to depend on the type of macronutrient 
that is substituted. However, effects may be different for diverse types of protein. 
For example, it was shown that satiety was acutely increased and energy intake was 
decreased after a whey diet compared with a casein diet [88]. 
 Furthermore, high protein diets may preserve or increase fat free mass and re-
duce fat mass during weight loss and weight regain, contributing to an improved 
body composition and metabolic profile. Layman et al. [89] found an improved body 
composition during weight loss in adult women, when proteins replaced carbohy-
drates. In a trial by Westerterp-Plantenga et al. [90], overweight and obese subjects 
who consumed 18% of energy as protein regained less weight (1 kg) during 3 
months after a weight loss period than subjects who consumed 15% of energy from 
protein (2 kg). In addition, body composition of the regained body mass was more 
favourable in the high protein group, in which no fat mass, but only fat free mass 
was regained, resulting in a lower percentage of body fat. 
Effects of bioactive peptides on blood pressure and coagulation 
Milk contains two major protein groups: caseins and whey proteins. Caseins are a 
mixture of related phosphoproteins, characterized as one of the most nutritive milk 
proteins, containing all of the common amino acids and being rich in the essential 
ones. They are a heterogeneous family of proteins, mainly αS1-, αS2-, β-, and κ-
caseins. Caseins account for almost 80% of total protein in bovine milk and exist 
primarily as calcium phosphate stabilized micellular complexes [91]. Whey protein is 
the name for a collection of globular proteins that can be isolated from whey, a by-
product of cheese manufactured from cow’s milk. Whey proteins account for 20% 
of total milk protein, and are also a heterogeneous group of proteins. They mainly 
consist of α-lactalbumin, β-lactoglobulin, and serum albumin [91]. 
 Both caseins and whey proteins are precursors of many different biologically ac-
tive peptides. These peptides are inactive within the protein sequence, requiring 
enzymatic proteolysis for release of the bioactive fragment from the protein precur-
sor. These fragments can be released either during gastrointestinal digestion or dur-
ing food processing, for example during fermentation with bacteria such as Lacto-
bacillus helveticus [92, 93]. One class of bioactive peptides derived from dairy pro-
tein is the group of the angiotensin-I-converting enzyme (ACE) inhibitory proteins. 
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ACE is a multifunctional enzyme, which plays a key physiological role in the regula-
tion of peripheral blood pressure. Associated with the renin-angiotensin system, 
ACE converts angiotensin I to the highly potent vasoconstrictor angiotensin II. Inhi-
bition of this enzyme prevents the formation of angiotensin II and will therefore re-
sult in reduced blood pressure. ACE-inhibitory peptides are present in the amino 
acid sequences of caseins, as well as in whey proteins [93, 94]. In this way, blood 
pressure is one feature of the metabolic syndrome that could be affected by dairy 
protein (Figure 2.3).  
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Figure 2.3. Inhibition of conversion from angiotensin I to angiotensin II by bioactive peptides derived 
from milk proteins. These peptides block the action of angiotensin converting enzyme (ACE) and may, in 
this way, lower blood pressure. 
 
However, most studies on the ACE-inhibitory effects of milk peptides have been 
performed in vitro, and the number of human studies is limited. Aihara et al. [95] 
performed a 4-week trial with 40 subjects with high-normal blood pressure and 
forty mild hypertensive subjects, receiving either powdered fermented milk tablets 
(12 g) or placebo tablets. They found decreases in systolic and diastolic blood pres-
sures by 3.2 mmHg (non-significant) and 5.0 mmHg (P<0.05), respectively, in the 
high-normal subjects. In the mild hypertensive subjects, systolic blood pressure was 
decreased by 11.2 mmHg (P<0.05) and diastolic pressure by 6.5 mmHg (P=0.055). In 
the study of Mizuno et al. [96], forty-eight subjects with high-normal blood pressure 
and eighty-three mild hypertensive subjects received casein hydrolysate (3.6 
mg/day) or placebo tablets for 6 weeks. In the high-normal group, non- significant 
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changes in both systolic (-3.1 mmHg) and diastolic (-0.3 mmHg) blood pressure were 
observed. Systolic blood pressure decreased significantly by 11.8 mmHg in the 
mildly hypertensive subjects, while diastolic blood pressure was decreased by 2.9 
mmHg. In a trial with thirty-nine hypertensive patients performed by Seppo et al. 
[97], skim milk fermented with Lactobacillus helveticus (150 mL/day) seemed to 
cause a reduction in blood pressure after 21 weeks, compared with skim milk fer-
mented with Lactococcus sp. However, after intention-to-treat analysis, no signifi-
cant differences between test product group and control group were observed. In 
addition, in a recent placebo-controlled trial in 135 mildly hypertensive subjects by 
Engberink et al., no effects of milk-derived peptides on blood pressure, ACE-activity 
or plasma angiotensin II concentrations were found after 8 weeks of treatment [98]. 
Also, bioavailability of these peptides is questionable [92], although one study has 
demonstrated the uptake of intact lactotripeptides [99]. Finally, the amount of ACE-
inhibitory peptides in non-enriched dairy products may simply be too low to play a 
significant role in blood pressure regulation. Taken together, human studies do cur-
rently not provide unequivocal evidence that bioactive peptides from dairy protein 
lower systolic or diastolic blood pressure. 
 Additionally, bioactive peptides in dairy protein can exert beneficial effects on 
the prothrombotic state characterizing the metabolic syndrome. A large number of 
similarities between blood clotting and milk clotting exist, including sequence iden-
tities between fibrinogen and some milk proteins, and some functional similarities. 
Casoplatelins are peptides derived from κ-casein that display antithrombotic activ-
ity. They show some sequence similarity to the interacting region of the fibrinogen 
γ-chain in platelet aggregation. Their inhibitory effect is probably due to the compe-
tition between antithrombotic peptides and the fibrinogen γ-chain for platelet re-
ceptors [93, 100]. Again, much of this antithrombotic activity has been measured in 
vitro, which does not necessarily imply antithrombotic activity in vivo. Human stud-
ies are lacking, but in vivo antithrombotic activity of milk peptides has been shown 
in some animal studies [101]. An overview of the effects of dairy protein on meta-
bolic syndrome components found in human studies is presented in Table 2.2. 
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Table 2.2. Overview of recent intervention studies on the effects of fermented dairy products or dairy 
protein on components of the metabolic syndrome. 
MetS 
compo-
nent 
Subjects Design Intervention Control Effects Authors 
Blood 
pressure 
40 HN +  
40 MH   
subjects 
Randomized, 
double blind,  
4 wk 
6 Powdered  
fermented milk  
tablets (12 g) 
Placebo  
tablets 
HN 
 
MH 
SBP 
DBP 
SBP 
DBP 
-3.2 mm Hg 
-5.0 mm Hg* 
-11.2 mm Hg* 
-6.5 mm Hg 
Aihara  
2005 [95] 
Blood 
pressure 
48 HN +  
83 MH  
subjects 
Randomized,  
single blind,  
6 wk 
Casein  
hydrolysate,  
3.6 mg/d 
Placebo  
tablets 
HN 
 
MH 
SBP 
DBP 
SBP 
DBP 
-3.1 mm Hg 
-0.3 mm Hg  
-11.8 mm Hg* 
-2.9 mm Hg 
Mizuno  
2005 [96] 
Blood 
pressure 
39  
hypertensive 
patients 
Randomized,  
21 wk 
Skim milk  
fermented with 
Lactobacillus 
helveticus 150 
mL/d 
Skim milk 
fermented 
with Lacto-
coccus sp. 
150 mL/d 
 SBP 
DBP 
-5.0 mm Hg  
-2.5 mm Hg 
Seppo  
2003 [97] 
TC, Total Cholesterol; HDL-C, High Density Lipoprotein Cholesterol; HN, High-Normal blood pressure; MH, 
Mild Hypertensive; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure. *P< 0.05 
Conclusion 
In conclusion, protein can play a role in body weight regulation by increasing satiety, 
resulting in reduced energy intake. In body weight loss and regain, protein may im-
prove body composition by preserving or increasing fat free mass and reducing fat 
mass. It also affects the serum lipid profile when compared to carbohydrates by de-
creasing both LDL and HDL cholesterol, but it improves the total:HDL ratio. Fur-
thermore, dairy proteins are precursors of bioactive peptides, which can inhibit 
ACE-activity and thereby reduce blood pressure, but evidence for such effects is cur-
rently not provided by human studies. 
Dairy fat 
The western diet provides approximately 90 grams of fat per day. Of this daily fat 
consumption, a substantial portion is supplied by dairy products [46]. High-fat dairy 
products are relatively rich in saturated fatty acids, especially in myristic (14:0), 
palmitic (16:0), and stearic (18:0) acids [102]. While stearic acid has little effect on 
the serum lipoprotein profile, myristic and palmitic acid are known to increase se-
rum LDL and HDL cholesterol concentrations. Intervention studies have also shown 
that replacing saturated fatty acids by cis-unsaturated fatty acids lowers the risk of 
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cardiovascular disease [103].To improve an atherogenic lipoprotein profile, it is cur-
rently recommended to reduce the intake of saturated fatty acids. 
 It is hypothesized that fat in milk, butter and cheese affects blood lipids differ-
ently due to matrix effects. Tholstrup et al. could not confirm different effects of fat 
in milk and butter, but found a moderately lower LDL cholesterol concentrations af-
ter a cheese diet compared to a butter diet [104]. Biong et al. [105] observed signifi-
cantly lower total cholesterol concentrations after a cheese diet than after a butter 
diet, while the difference in LDL cholesterol almost reached statistical significance. 
These observations could be related to the fact that the diets differed in calcium 
content, with the highest calcium intake from the cheese diet. Similar results were 
found by Nestel et al. [106] in mildly hypercholesterolemic subjects. The macronu-
trient composition of the diets was similar, but no data on calcium contents were 
given. 
Effects of CLA 
Recently, much attention has been paid to conjugated linoleic acid (CLA). CLA is a 
positional and geometric conjugated isomer of linoleic acid. Two common isomers 
of CLA exist, trans10,cis12-CLA (t10,c12-CLA) and cis9,trans11-CLA (c9,t11-CLA), 
which may have distinct metabolic effects. The c9,t11 isomer accounts for over 90% 
of the total CLA intake from food. Milk fat is relatively rich in c9,t11-CLA, although 
levels are still low (less than 0.5% of total milk fat). Many animal studies have shown 
positive effects of CLA on body weight and fat deposition [107, 108]. In addition, 
some animal trials reported cholesterol-lowering effects of CLA [109]. However, re-
sults of human studies are less consistent. In a recent meta-analysis, it was found 
that, given at a dose of 3.2 g/day, CLA produces a modest loss in body fat in humans 
[110]. In contrast, a number of reviews concluded that CLA is not effective in reduc-
ing body weight and plasma cholesterol concentrations in humans, and that espe-
cially t10,c12-CLA may actually adversely affect human health, for example by in-
ducing insulin resistance [107-109]. In addition, effects, if any, are only observed at 
high intakes (>3 g/day). Therefore, the amount of CLA in dairy fat is too low to play a 
significant role in the prevention of the metabolic syndrome. 
Conclusion 
To reduce cardiovascular risk, it is important to limit the intake of saturated fatty 
acids. Therefore, the consumption of low-fat instead of high-fat dairy products is 
strongly recommended. While different responses to fat from different dairy 
products have not been confirmed, other dairy constituents, such as calcium, seem 
to influence the effects. It is not likely that CLA, in the amounts present in dairy 
products, have any risk reducing effects. 
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Final conclusion 
Several epidemiological studies have suggested that consumption of dairy products 
contribute to a decreased risk to develop the metabolic syndrome. If so, an impor-
tant question is which components of dairy products are actually responsible for the 
favourable effects. Calcium and protein have been reported to positively affect sev-
eral components of the metabolic syndrome. The fat fraction of dairy products does 
not seem to contain any bioactive compounds in this respect. The different compo-
nents may act synergistically leading to augmented beneficial effects, but this cer-
tainly warrants further investigation. Without doubt, the intake of saturated fatty 
acids should be limited. Therefore, it is important to focus on low-fat instead of 
high-fat dairy products.  
 Taken together, evidence exists that dairy products may play a role in the pre-
vention and treatment of the metabolic syndrome. However, most of the studies 
focussed on single features of the metabolic syndrome. In addition, not all features 
of the syndrome (e.g. the inflammatory and prothrombotic state) have been studied 
in depth. Furthermore, most research focussed on single dairy constituents, while 
studies on the effects of dairy products mainly had an observational design. There-
fore, as yet, there is insufficient evidence to decisively conclude that dairy products 
play a role in the development of the metabolic syndrome. Hence, more experimen-
tal research is needed to fully elucidate the physiological effects of an increased 
consumption of dairy products as related to the metabolic syndrome, as well as the 
mechanisms involved. 
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ABSTRACT 
 
Epidemiological studies have indicated a negative relation between low-fat 
dairy consumption and the metabolic syndrome. However, evidence from in-
tervention studies is scarce. Our aim was to investigate the effects of daily 
consumption of low-fat dairy products on metabolic risk parameters in over-
weight and obese men and women. Thirty-five healthy subjects (BMI >27 
kg/m
2
) consumed daily for 8 weeks in random order low-fat dairy products 
(500 mL low-fat milk and 150 g low-fat yogurt) or carbohydrate-rich control 
products (600 mL fruit juice and 3 fruit biscuits). Compared with the control 
period, the decrease in plasma 1,25-dihydroxy vitamin D3 concentrations of 9 ± 
27 pmol/L after the low-fat dairy period confirmed dietary compliance. Systolic 
blood pressure was decreased by 2.9 mmHg (95% confidence interval (CI), -5.5 
to -0.3 mmHg; P=0.027) after dairy consumption compared with control, while 
the difference in diastolic blood pressure did not reach statistical significance 
(95% CI, -3.4 to 0.3 mmHg; P=0.090). Low-fat dairy consumption decreased 
HDL-cholesterol concentrations by 0.04 mmol/L (95% CI, -0.07 to -0.01 
mmol/L; P=0.021) and apoA-1 concentrations by 0.04 g/L (95% CI, -0.07 to         
-0.01 g/L; P=0.016) compared with control. Serum total cholesterol, LDL-
cholesterol, apoB, triacylglycerols, non-esterified fatty acids, glucose, insulin, 
C-reactive protein and plasminogen activator inhibitor-1 were unchanged. We 
conclude that in overweight and obese subjects, daily intake of low-fat dairy 
products for 8 weeks decreased systolic blood pressure, but did not improve 
other metabolic risk factors related to the metabolic syndrome. 
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Introduction 
Cross-sectional and prospective cohort studies have suggested that an increased 
consumption of low-fat dairy products lowers the risk to develop the metabolic 
syndrome [36-40, 43, 44], a constellation of metabolic risk factors that increases the 
risk to develop cardiovascular disease and type 2 diabetes mellitus [34]. However, 
other studies did not find such an association [41, 42]. Further, due to the nature of 
these studies, it cannot be concluded that increased consumption of dairy products 
is causally related to (some of the components of) the metabolic syndrome. Inter-
vention studies addressing the effects of dairy products on the metabolic syndrome 
are missing. As yet, intervention trials only studied single, major dairy components 
(e.g. calcium or protein) or assessed the effects of dairy on one single or a few of 
the syndrome components [58, 59, 111], or as part of energy deficit diets [60]. In 
the present study, we therefore examined the effects of low-fat dairy products as 
part of the normal diet on the multiple risk parameters of the metabolic syndrome 
in overweight and obese subjects. These subjects are at increased risk of metabolic 
disorders, and often display one or more characteristics of the metabolic syndrome.  
Methods 
Study population 
The Medical Ethics Committee of Maastricht University approved the study. Sub-
jects, recruited in Maastricht and surroundings, gave their written informed consent 
before they entered the screening procedure. During the screening visits, height, 
weight, waist circumference and blood pressure were measured. Blood pressure 
was measured three times on the non-dominant arm using a digital automatic blood 
pressure monitor (Omron, Kyoto, Japan), while seated. The mean of the last two 
measurements was used for further analysis. Also, two fasting blood samples, sepa-
rated by a period of at least 3 days, were drawn to determine serum lipid and lipo-
protein concentrations. Subjects were enrolled in the study when they met the fol-
lowing criteria: 18-70 y; BMI >27 kg/m
2
 and/or waist circumference >88 cm in wom-
en or >102 cm in men; no active cardiovascular disease, familial hypercholesterole-
mia, or severe medical conditions that might interfere with the study; no abuse of 
alcohol or drugs; no pregnancy or breastfeeding; stable body weight during the last 
3 months; and dairy (milk, yogurt and cheese products) consumption <500 g per 
day, as asked during the screening visits. Forty overweight and obese volunteers (10 
male and 30 female) were selected. One subject withdrew because the protocol 
was too demanding and 3 subjects withdrew because of personal circumstances. 
One subject was excluded from the analyses due to non-adherence to the protocol. 
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Subjects were asked not to change their dietary habits, use of alcohol, level of phys-
ical exercise, smoking habits or use of oral contraceptives during the study. 
Study design and intervention 
The study had a crossover design and consisted of two intervention periods of 8 
weeks, separated by a washout period of at least 2 weeks. At the start of both pe-
riods and after 4, 7, and 8 weeks of intervention, subjects visited the university. Sub-
jects were randomly allocated to one of two treatment groups. During the first pe-
riod, the first group (n=17) received dairy products, while they received control 
products during the second period, and vice versa for the second group (n=18). In 
the dairy period, subjects consumed 500 mL low-fat (1.5%) milk and 150 g low-fat 
(1.5%) yogurt (Campina, Woerden, The Netherlands) per day. In the control period, 
subjects consumed 600 mL fruit juice (Refresco, Dordrecht, The Netherlands) and 43 
g fruit biscuits (3 pieces) (Verkade, Zaandam, The Netherlands) per day. Subjects re-
ceived at each visit the products needed till the next visit, free of charge. The prod-
ucts were packed in daily portions and subjects were instructed to consume the 
products throughout the day. The total energy contents of the dairy and control 
products were comparable (Table 3.1). At the end of each experimental period, 
energy and nutrient intakes during the previous 4 weeks were estimated using a va-
lidated food frequency questionnaire [112]. Subjects were asked to record daily any 
signs of illness, use of medication, or deviations from the study protocol in a diary. 
 
Table 3.1. Composition of dairy and control products. 
 Dairy Control 
 Product 
content 
% of subjects’ 
daily intake 
Product 
content 
% of subjects’ 
daily intake 
Energy (MJ) 1.5 16.3 ± 3.7 1.7 18.9 ± 3.4 
Protein (g) 24.4 24.0 ± 5.0 2.8 3.3 ± 0.7 
Fat total (g) 9.8 12.8 ± 3.6 3.8 5.5 ± 1.4 
SFA (g) 6.3 21.2 ± 5.9 1.6 6.6 ± 2.1 
MUFA (g) 2.4 10.4 ± 3.7 0  -  
PUFA (g) 0.3 2.0 ± 0.5 0.6 3.9 ± 1.0 
TFA (g) 0.4 23.6 ± 14.5 0  -  
Carbohydrates (g) 39.7 15.7 ± 4.3 85.0 30.6 ± 6.0 
Mono- and disaccharides (g) 39.2 30.4 ± 9.9 70.2 45.1 ± 11.0 
Fiber (g) 0 -  2.7 12.1 ± 3.5 
Cholesterol (mg) 27.5 13.7 ± 3.7 0  -  
Calcium (mg) 800 53.2 ± 9.2 75 9.0 ± 3.1 
All values are means ± SD. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyun-
saturated fatty acids; TFA, trans fatty acids. 
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Blood pressure and body weight 
Blood pressure was measured at each visit following the same procedures as during 
the screening visits. Thus, subjects were already familiarized with the measure-
ments. Subjects on antihypertensive medication did not alter their use of medica-
tion during the study. Body weight was measured at each visit without shoes and 
heavy clothing.  
Blood sampling and analyses 
At weeks 0, 4, 7, and 8 , blood samples were taken after an overnight fast. Venous 
blood was sampled using a vacutainer system (Becton Dickinson Vacutainer Sys-
tems, Franklin Lakes, USA). Blood was drawn into serum separator tubes for analysis 
of lipids, apolipoproteins (apo) A-1 and B, and C-Reactive Protein (CRP). After clot-
ting at room temperature for at least 30 min, serum was obtained by centrifugation 
at 2500 g for 30 min at room temperature and stored at -80°C. In addition, EDTA 
tubes were drawn for measurement of lipoprotein particles, insulin and 1,25-
dihydroxy-vitamin D3, sodium citrate tubes for plasminogen activator inhibitor-1 
(PAI-1) and sodium fluoride (NaF) tubes for glucose and non-esterified fatty acid 
(NEFA) concentrations. These tubes were kept on ice and centrifuged within 1 hour 
after venipuncture at 2500 g for 30 min at 4°C, and samples were snap-frozen in liq-
uid nitrogen and stored at -80°C.  
 Concentrations of total cholesterol (CHOD-PAP method; Roche, Basel, Switzer-
land), HDL-cholesterol (precipitation method; Roche, Basel, Switzerland), apolipo-
proteins A-1 and B (UNI-KIT apoA-1 and apoB; Roche, Basel, Switzerland) and tri-
acylglycerol (TAG) with correction for free glycerol (GPO Trinder; Sigma Diagnostics, 
St. Louis, USA) were determined in all samples. LDL cholesterol was calculated using 
the Friedewald equation [113]. Lipoprotein particles were measured in pooled sam-
ples from weeks 7 and 8 by NMR spectroscopy (Liposcience, Raleigh, USA) and NEFA 
by an enzymatic assay (WAKO, Neuss, Germany). Glucose was measured in all sam-
ples (Horiba ABX, Montpellier, France) and insulin concentrations were determined 
in samples from weeks 7 and 8 (Mercodia, Uppsala, Sweden). Insulin sensitivity was 
calculated using a homeostasis model assessment for insulin resistance (HOMAir) 
[114]. Hs-CRP was measured in all samples (Kamiya Biomedical Company, Seattle, 
USA). PAI-1 activity was measured in citrated plasma from weeks 7 and 8 (Chro-
molize PAI-1; Biopool, Umea, Sweden). Results of two subjects could not be used 
due to extreme low concentrations (<0.2 U/mL). To check for subjects’ compliance, 
serum concentrations of 1,25-dihydroxy vitamin D3 were measured in pooled sam-
ples from weeks 7 and 8 (Immunodiagnostic Systems, Boldon, United Kingdom). For 
lipids, lipoproteins, hs-CRP, and glucose, the within-run and between-run coeffi-
cients of variation (CV) were below 2.5% and for insulin below 5%. For NMR analys-
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es, CVs have been reported elsewhere [115]. For PAI-1 and 1,25-dihydroxy vitamin 
D3, the number of runs (n=2) was too limited to provide informative CVs. 
Statistics 
Statistical analyses were performed using SPSS 16 for Macintosh OS X package 
(SPSS, Chicago, USA). For each subject, results of measurements taken at weeks 7 
and 8 of each intervention period were averaged before statistical analysis. Differ-
ences in endpoints of the dairy and control period, which were normally distributed 
as indicated by the Shapiro-Wilk test, were evaluated by paired t-test analysis. The 
presence of time and sequence effects, which were not present, was tested as de-
scribed [116]. Also, values for the parameters measured at the start of the two die-
tary periods were comparable, as tested by paired t-tests. Finally, responses did not 
differ between men and women, as tested by unpaired t-tests. Values are presented 
as means ± standard deviation. A P-value <0.05 was considered as statistically signif-
icant.  
Results 
Subjects, diets and dietary adherence 
Baseline characteristics of the subjects are shown in Table 3.2. Mean body weights 
at the end of each period did not differ between the diets (P=0.561) and were 91.1 
± 13.1 kg on the dairy diet and 91.3 ± 13.5 kg on the control diet. Changes in body 
weight did not correlate with changes in any of the other parameters. Total energy 
intake was not different in the dairy and control condition (Table 3.3). Changes in 
the intakes of protein, fat, fatty acids, carbohydrates, fibre, cholesterol and calcium 
reflected the exchange of the low-fat dairy products for the carbohydrate-rich 
products. Besides the experimental products, there were no differences in dairy 
consumption between the two periods, except for a slightly higher intake of milk 
drinks in the control period (150 ± 141 mL/d) than in the dairy period (102 ± 126 
mL/d, P=0.022). From the number of products returned by the subjects, it was cal-
culated that the mean daily intake was 500 mL milk and 150 g yogurt, or 601 mL 
fruit juice and 43 g fruit biscuits, indicating a compliance of virtually 100%. Plasma 
concentrations of 1,25-(OH)2D3 were significantly lower (P=0.034) after the dairy in-
tervention (119 ± 30 pmol/L) than after control (128 ± 37 pmol/L). 
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Table 3.2. Baseline characteristics of subjects. 
 Men Women All 
 n = 10 n = 25 n = 35 
Age (y) 52.3 ± 10.7 47.2 ± 14.2 49.5 ± 13.2 
BMI (kg/m
2
) 31.1 ± 1.2 32.4 ± 4.4 32.0 ± 3.8 
Waist circumference (cm) 111 ± 6.0 105 ± 10.5 106 ± 9.7 
Systolic blood pressure (mmHg) 138 ± 14.4 134 ± 21.9 135 ± 19.9 
Diastolic blood pressure (mmHg) 94 ± 10.9 86 ± 13.6 88 ± 13.2 
Use of antihypertensive medication n = 4 n = 6 n = 10 
Total cholesterol (mmol/L) 6.31 ± 0.9 5.96 ± 1.1 6.06 ± 1.0 
HDL cholesterol (mmol/L) 1.28 ± 0.2 1.45 ± 0.4 1.40 ± 0.4 
LDL cholesterol (mmol/L) 4.32 ± 0.7 3.92 ± 1.0 4.04 ± 1.0 
Triacylglycerols (mmol/L) 1.54 ± 0.5 1.29 ± 0.5 1.36 ± 0.5 
Glucose (mmol/L) 6.11 ± 0.6 5.51 ± 0.5 5.68 ± 0.6 
All values are means ± SD. 
 
 
Table 3.3. Mean daily dietary intakes during the intervention periods estimated from food frequency 
questionnaires. 
 Dairy Control 
Energy (MJ) 9.4 ± 2.1 9.2 ± 1.6 
Protein (En%) 19.2 ± 3.2* 16.0 ± 2.4 
Fat total (En%) 33.1 ± 4.7* 29.9 ± 4.9 
SFA (En%) 12.8 ± 2.1* 10.7 ± 2.1 
MUFA (En%) 10.3 ± 1.9* 9.2 ± 1.9 
PUFA (En%) 6.6 ± 1.1 6.6 ± 1.2 
TFA (En%) 0.9 ± 0.3 0.8 ± 0.3 
Carbohydrates (En%) 45.9 ± 6.1* 52.5 ± 5.8 
Mono- and disaccharides (En%) 25.6 ± 6.1* 30.0 ± 5.5 
Alcohol (En%) 1.9 ± 2.3 1.7 ± 2.3 
Fiber (g/MJ) 2.3 ± 0.6* 2.6 ± 0.7 
Cholesterol (mg/MJ) 23.3 ± 5.6* 19.7 ± 4.5 
Calcium (mg) 1550 ± 281* 931 ± 291 
All values are means ± SD. *Significantly different from control, P<0.05. SFA, saturated fatty acids; MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TFA, trans fatty acids. 
Serum lipids and (apo)lipoproteins 
No statistically significant changes in serum concentrations of total cholesterol, LDL-
cholesterol and TAG were observed (Table 3.4). Also, the concentration of small 
dense LDL particles, the mean LDL particle size, and the numbers of LDL and VLDL 
particles did not differ between the diets. The mean VLDL particle size was de-
creased by 2.46 ± 6.11 nm (P=0.024). HDL-cholesterol was reduced by 0.04 ± 0.09 
mmol/L (P=0.021) and the number of HDL particles was decreased by 1.07 ± 2.14 
µmol/L (P=0.006). The mean HDL particle size however was not different between 
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the diets. Dairy consumption increased the total to HDL-cholesterol ratio by 0.13 ± 
0.37 (P=0.048). There was no difference in concentrations of apolipoprotein B, while 
apoA-1 concentrations were decreased by 0.04 ± 0.10 g/L (P=0.016). Concentrations 
of NEFA were not different between the dairy and control period. Changes in total, 
HDL-, and LDL-cholesterol, apolipoproteins, NEFA and TAG were not correlated with 
baseline values.  
 
Table 3.4. Effects of dairy consumption on serum lipids and lipoprotein concentrations. 
 Dairy Control Absolute 
change 
Relative 
change 
(%) 
95% CI for 
absolute 
change 
P for 
absolute 
change 
Total cholesterol 
 (mmol/L) 
6.21 ± 1.04 6.23 ± 1.01 -0.02 ± 0.43 -0.2 -0.17 to 0.13 0.774 
HDL cholesterol  
 (mmol/L) 
1.40 ± 0.34 1.44 ± 0.34 -0.04 ± 0.09 -2.7 -0.07 to -0.01 0.021 
LDL cholesterol  
 (mmol/L) 
4.12 ± 0.98 4.09 ± 0.93 0.03 ± 0.43 1.3 -0.12 to 0.18 0.667 
Total:HDL 
 ratio 
4.60 ± 1.07 4.47 ± 1.00 0.13 ± 0.37 3.0 0.00 to 0.26 0.049 
VLDL particles 
 (nmol/L) 
70.1 ± 30.6 69.0 ± 28.9 1.18 ± 20.3 5.9 -5.80 to 8.15 0.734 
LDL particles  
 (nmol/L) 
1427 ± 352 1432 ± 331 -4.29 ± 151 -0.0 -56.1 to 47.5 0.867 
Small LDL parti- 
 cles (nmol/L) 
919 ± 397 897 ± 395 22.1 ± 215 7.9 -51.7 to 95.8 0.547 
HDL particles 
 (µmol/L) 
30.8 ± 4.7 31.9 ± 4.9 -1.07 ± 2.15 -3.4 -1.81 to -0.33 0.006 
VLDL particle size 
 (nm) 
50.4 ± 7.5 52.8 ± 7.2 -2.46 ± 6.11 -4.1 -4.56 to -0.36 0.024 
LDL particle size 
 (nm) 
20.9 ± 0.62 20.9 ± 0.66 -0.02 ± 0.38 -0.1 -0.15 to 0.12 0.794 
HDL particle size 
 (nm) 
8.88 ± 0.4 8.91 ± 0.4 -0.03 ± 0.14 -0.4 -0.08 to 0.02 0.166 
Triacylglycerols 
 (mmol/L) 
1.46 ± 0.61 1.50 ± 0.56 -0.04 ± 0.37 -1.3 -0.16 to 0.09 0.552 
Apolipoprotein 
 A-1 (g/L) 
1.49 ± 0.23 1.53 ± 0.24 -0.04 ± 0.10 -2.5 -0.07 to -0.01 0.016 
Apolipoprotein B 
 (g/L) 
1.06 ± 0.19 1.07 ± 0.18 -0.01 ± 0.07 -1.1 -0.04 to 0.01 0.309 
NEFA 
 (µmol/L) 
358 ± 147 346 ± 124 12.3 ± 94.1 5.8 -20.0 to 44.5 0.446 
All values are means ± SD. NEFA, non-esterified fatty acids. 
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Blood pressure 
Systolic blood pressure was significantly decreased by 2.9 ± 7.4 mmHg (P=0.027, 
Table 3.5) after dairy consumption. Diastolic blood pressure was non-significantly 
decreased by 1.6 ± 5.2 mmHg (P=0.090). Exclusion of subjects using blood pressure 
lowering medication (n=10) did not alter these outcomes. In fact, in non-users, 
systolic blood pressure was 4.2 ± 7.6 mmHg (95% CI, -7.4 to -1.1 mmHg; P=0.010) 
lower after dairy than after control, while diastolic blood pressure was reduced by 
1.8 ± 4.5 mmHg (95% CI, -3.7 to 0.0 mmHg; P=0.055). Changes in blood pressure 
were not correlated with baseline values.  
 
Table 3.5. Effects of dairy consumption on glucose, insulin, CRP, and PAI-1 concentrations, blood pres-
sure and HOMAir. 
 Dairy Control Absolute 
change 
Relative 
change 
(%) 
95% CI for  
absolute 
change 
P for  
absolute 
change 
Systolic BP 
 (mmHg) 
128.4 ± 19.2 131.3 ± 18.3 -2.91 ± 7.4 -2.2 -5.45 to -0.34 0.027 
Diastolic BP 
 (mmHg) 
85.4 ± 10.2 87.0 ± 11.5 -1.55 ± 5.2 -1.5 -3.35 to 0.25 0.090 
Glucose 
 (mmol/L) 
5.75 ± 0.63 5.74 ± 0.66 0.01 ± 0.034 0.4 -0.11 to 0.13 0.851 
Insulin 
 (mU/L) 
11.2 ± 5.5 11.7 ± 7.0 -0.49 ± 3.12 1.0 -1.58 to 0.60 0.371 
HOMAir 
 
2.90 ± 1.55 3.02 ± 1.86 -0.12 ± 0.89 2.0 -0.43 to 0.19 0.433 
CRP 
 (mg/L) 
4.07 ± 3.50 4.54 ± 4.09 -0.47 ± 1.74 6.3 -1.10 to 0.17 0.147 
PAI-1 
 (U/mL) 
22.9 ± 18.7 24.8 ± 18.0 -1.91 ± 8.92 6.3 -5.08 to 1.25 0.227 
All values are means ± SD. BP, blood pressure; HOMAir, homeostasis model assessment for insulin resis-
tance; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1. 
Glucose, insulin, C-Reactive Protein, and Plasminogen Activator Inhibitor-1 
There were no significant changes in plasma glucose and insulin concentrations, and 
HOMAir between dairy and control conditions (Table 3.5). Serum CRP concentra-
tions and plasma concentrations of active PAI-1 were also unaffected by dairy con-
sumption. Changes in glucose and CRP were not correlated with baseline values.  
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Discussion 
In the present study, we found that daily consumption of 500 mL low-fat milk and 
150 g low-fat yogurt did not improve metabolic risk parameters in overweight and 
obese subjects, except for a reduction in systolic blood pressure. In fact, HDL-
cholesterol concentrations were decreased after dairy consumption. Subjects’ com-
pliance was confirmed by the expected decrease in plasma concentrations of 1,25-
(OH)2D3. In addition, the food frequency questionnaires showed that daily calcium 
intake was increased by more than 600 mg. Since subjects who do not use low-fat 
dairy products in daily life may consume carbohydrate-rich drinks and foods instead, 
fruit juice and fruit biscuits were used as control products. Low-fat dairy products 
were used instead of high-fat products, as it is well established that the intake of sa-
turated fatty acids should be as low as possible, as these fatty acids may unfavoura-
bly affect the serum lipoprotein profile and insulin sensitivity [117, 118]. Thus, in 
our controlled 8-week intervention study we did not observe results indicating that 
consumption of low-fat dairy products instead of carbohydrate-rich products may 
protect against the development of the metabolic syndrome, unlike what can be 
suggested based on epidemiological studies.  
 Several components of the low-fat dairy products have been reported to affect 
metabolic risk markers. First of all, a few intervention studies have been performed 
on the effects of calcium supplementation on the serum lipid and lipoprotein profile 
[49-51, 53]. These studies mostly showed reduced concentrations of total and LDL-
cholesterol. One study also reported an increased concentration of HDL-cholesterol 
[49]. Denke and colleagues [53] observed beneficial effects of calcium at intakes of 
2200 mg per day, compared with 410 mg in the control condition. Others have 
compared calcium intakes of 1850-2200 mg in the calcium-rich period with 900-
1200 mg in the control period and did observe positive effects [49-51]. We, howev-
er, found no effects of increasing the intake of low-fat dairy products on serum con-
centrations of total and LDL-cholesterol. It might be speculated that the calcium in-
take of our subjects during the control period was already too high to find effects of 
additional calcium consumption. However, this suggestion is not supported by the 
results of the before mentioned supplementation studies [49-51] that used even 
higher calcium intakes during the control period.  
 Effects of protein, another important constituent of dairy products, on the se-
rum lipid profile are conflicting. Krauss et al. [78] found slightly increased concentra-
tions of HDL- and LDL-cholesterol after a high protein diet compared with a high 
carbohydrate diet, whereas these values were decreased by protein versus carbo-
hydrates in the OmniHeart trial [80]. In both studies, however, the total to HDL-
cholesterol ratio was decreased on the high-protein diet. We did not find any effects 
of dairy consumption on LDL-cholesterol, but did observe a decrease in HDL-
cholesterol, apolipoprotein A1, and HDL particle number. As a consequence, the to-
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tal to HDL-cholesterol ratio was increased. This reduction in HDL-cholesterol is in 
line with the OmniHeart results, and might therefore be a result of the exchange of 
carbohydrate for protein intake, when subjects switch from the control diet to the 
low-fat dairy diet. However, dietary protein content in the OmniHeart trial 
amounted 15 En% in the carbohydrate diet and 25 En% in the protein diet. This dif-
ference was accomplished by adjusting meat and plant protein, while dairy protein 
was similar in both diets. In our study, difference in protein intake between the two 
diets was only 3.2 En%. In addition, Krauss et al. observed a significant increase in 
LDL particle diameter after a high protein diet [78]. We, however, did not find 
changes in LDL or HDL particle sizes, but we did observe a decrease in VLDL particle 
diameter after the dairy intervention. Larger VLDL particles are thought to be pre-
cursors of small dense LDL particles [119] and have been inversely associated with 
cardiovascular disease risk [120]. This decrease in VLDL particle size would therefore 
imply a beneficial metabolic effect of dairy consumption, although this may be a 
chance finding as the change was not accompanied by the frequently related 
changes in other lipoproteins, such as in LDL particle diameter [120]. 
 It should be noted however that besides protein, carbohydrate and calcium, al-
so the intake of fat and fatty acids was different between the two diets. Although 
we used low-fat dairy products, total fat consumption was increased by 3.2 En%, sa-
turated fatty acid intake by 2.1 En%, and monounsaturated fatty acid intake by 1.1 
En%.  It can be estimated that this would have caused an increase of 0.07 mmol/L in 
total cholesterol, of 0.06 mmol/L in LDL-cholesterol, and of 0.03 mmol/L in HDL-
cholesterol [117]. Though small, these changes in fat and fatty acids intakes should 
also be taken into account when discussing the effects of low-fat dairy product on 
the serum lipoprotein profile and the other metabolic risk markers. 
 We observed a 2.9 mmHg decrease in systolic blood pressure by dairy con-
sumption. This decrease is comparable to the results found in the well-known 
DASH-trial, which compared a diet high in fruits, vegetables and dairy products with 
a diet rich in fruits and vegetables alone [59]. This could be a specific effect of dairy 
constituents, but it could also be a result of the fact that carbohydrate intake was 
reduced and replaced by some protein and fat. In fact, Appel et al. [80] have re-
ported that protein and fat decreased systolic and diastolic blood pressure to the 
same extent when compared with carbohydrates. Additionally, a meta-analysis 
showed that calcium supplementation at a mean dose of 1200 mg/d reduced systol-
ic blood pressure by 1.9 mmHg and diastolic BP by 1.0 mmHg [73]. In people with 
habitual calcium intakes <800 mg/d, somewhat larger reductions were found (-2.6 
and -1.3 mmHg for systolic and diastolic blood pressure, respectively), which is 
comparable to the effects we observed in this study. Further, Van Beresteijn et al. 
[121] observed a larger decrease in systolic blood pressure after 6 weeks consump-
tion of normal milk than after milk depleted in calcium, phosphorus, potassium and 
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magnesium. Thus, results suggest that both the proteins and the minerals from milk 
contribute to the antihypertensive action of milk. 
 Studies on dairy or calcium effects on PAI-1 or other fibrinolytic players are very 
limited. Mennen et al. [122] found a negative relation between dairy products and 
tissue-type plasminogen activator antigen (t-PA-Ag), which might imply a beneficial 
effect on fibrinolysis. However, we did not observe effects of dairy consumption on 
PAI-1 in our study. 
 Although observational studies suggest an inverse association between calcium 
intake and the risk of type 2 DM, evidence from human intervention trials is very li-
mited [123]. In a study by Zemel and colleagues, a high-dairy diet reduced circulat-
ing insulin concentrations [58]. Although subjects maintained their body weight, ef-
fects were possibly due to an improvement in body composition. Though controver-
sial [124], a number of studies have indicated that saturated fatty acids may have 
deleterious effects on insulin sensitivity [118, 125]. Nonetheless, we did not detect 
any effects of dairy consumption on glucose or insulin concentrations, possibly due 
to the fact that glucose and insulin concentrations of our subjects were within the 
normal range.  
 In summary, the results of the present study indicate that in overweight and 
obese subjects, daily consumption of low-fat dairy products compared with carbo-
hydrate-rich products for 8 weeks decreased systolic blood pressure, but did not 
have beneficial effects on other metabolic risk markers.  
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ABSTRACT 
 
Although increased concentrations of plasma inflammatory markers are not 
one of the criteria to diagnose the metabolic syndrome, low-grade systemic in-
flammation is receiving large attention as a metabolic syndrome component 
and cardiovascular risk factor. As several epidemiological studies have sug-
gested a negative relationship between the low-fat dairy consumption and the 
metabolic syndrome, we decided to investigate in an intervention study the ef-
fects of low-fat dairy consumption on inflammatory markers and adhesion mo-
lecules in overweight and obese subjects. Thirty-five healthy subjects (BMI >27 
kg/m
2
) consumed, in random order, low-fat dairy products (500 mL low-fat 
milk and 150 g low-fat yogurt) or carbohydrate-rich control products (600 mL 
fruit juice and 3 fruit biscuits) daily for 8 weeks. Plasma concentrations of   
TNF-α were decreased by 0.16 ± 0.50 pg/mL (P=0.070) and soluble TNF-α re-
ceptor-1 (s-TNFR-1) was increased by 110.0 ± 338.4 pg/mL (P=0.062) after the 
low-fat dairy period compared with control. s-TNFR-2 was increased by 227.0 ± 
449.0 pg/mL (P=0.020) by the dairy intervention. As a result, the TNF-α index, 
defined as the TNF-α / s-TNFR2 ratio, was decreased by 0.000053 ± 0.00012 
(P=0.015) after the dairy diet. Low-fat dairy consumption had no effect on IL-6, 
monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion mole-
cule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) concentra-
tions. Our results indicate that in overweight and obese subjects, low-fat dairy 
consumption compared with carbohydrate-rich product consumption for 8 
weeks may increase concentrations of soluble TNF-α receptors, but has no ef-
fects on other markers of chronic inflammation and endothelial function. 
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Introduction 
The metabolic syndrome is a metabolic disorder that strongly enhances the risk to 
develop cardiovascular diseases (CVD) and type 2 diabetes mellitus. Abdominal ob-
esity, atherogenic dyslipidemia, hypertension, insulin resistance, a pro-thrombotic 
state, and a low-grade pro-inflammatory state have now been identified as compo-
nents of the metabolic syndrome that relate to CVD risk. Although inflammatory 
markers are currently not included in the ATP III or WHO diagnostic criteria for the 
metabolic syndrome [13], low-grade systemic inflammation is receiving large atten-
tion as a metabolic syndrome component and cardiovascular risk factor. Inflamma-
tory markers such as C-Reactive Protein (CRP) [126], IL-6 [127], TNF-α [128], and fi-
brinogen [129], among others, have been linked to the metabolic syndrome. 
 The consumption of dairy products has been inversely associated with the pre-
valence or incidence of the metabolic syndrome in a number of epidemiologic stu-
dies [36-40, 43, 44]. In the CARDIA study [43], for example, the intake of dairy prod-
ucts was negatively correlated with the development of obesity, dyslipidemia, glu-
cose intolerance, and hypertension over the next 10 years in overweight subjects. 
However, the relation between dairy consumption on the chronic inflammatory 
state linked to the metabolic syndrome has not yet been studied in depth. Recently, 
Zemel et al. reported positive effects of dairy and calcium intake on inflammatory 
markers, including TNF-α, IL-6 and adiponectin, in mice [111]. Moreover, they ob-
served reduced plasma concentrations of CRP and increased concentrations of 
plasma adiponectin in obese human subjects after a eucaloric or hypocaloric high-
dairy diet [111]. Therefore, we investigated in this intervention study with over-
weight and obese human subjects the effects of low-fat milk and yogurt consump-
tion on a broad range of inflammatory markers and adhesion molecules.  
Methods 
Study population 
The study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and all procedures involving human subjects were approved by the Medical 
Ethics Committee of Maastricht University. Written informed consent was obtained 
from all subjects. The study protocol has been previously reported into detail [130]. 
Briefly, 40 male and female subjects were recruited in Maastricht and surroundings 
by advertisements in local newspapers and in the University Hospital newsletter, 
and by posters in university and hospital buildings. During the screening visits, 
weight, height, waist circumference, and blood pressure were measured. Two fast-
ing blood samples, separated by a 3-day period, were taken for determination of se-
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rum lipid and lipoprotein concentrations. Subjects were enrolled in the study when 
they met the following criteria: 18-70 y of age; body mass index (BMI) >27 kg/m
2
 or 
waist circumference >88 cm (women) or >102 cm (men); no active cardiovascular 
disease, familial hypercholesterolemia, or other conditions that might interfere with 
the study outcomes; no pregnancy or breastfeeding; no abuse of alcohol or drugs; 
stable body weight during the past 3 months; and dairy (milk, yogurt and cheese 
(products)) <500 g per day, as asked during the screening visits. Ten male and 30 
female subjects were selected. Four subjects withdrew for personal reasons and 
one subject was excluded from the analyses due to non-adherence to the protocol. 
Thirty-five subjects (10 male and 25 female, of which 12 pre- and 13 post-
menopausal) were used for analyses. Subjects were asked not to change their dieta-
ry habits, level of physical exercise, use of alcohol, smoking habits, or use of oral 
contraceptives during the study period.  
Study design and intervention 
This study consisted of two intervention periods of 8 weeks, in a crossover design, 
separated by a washout period of at least 2 weeks. Subjects were randomly allo-
cated to one of two treatment groups. The first group  (n=17) consumed low-fat 
dairy products as a dietary supplement during the first intervention period, and car-
bohydrate-rich control products during the second intervention period, and vice 
versa for the second group of subjects (n=18). The subjects maintained their habi-
tual diet during the entire study. The dairy products consisted of 500 mL low-fat 
(1.5% w/w) milk and 150 g low-fat (1.5% w/w) yogurt (Campina, Woerden, The 
Netherlands) per day. The control products consisted of 600 mL fruit juice (Refresco, 
Dordrecht, The Netherlands) and 43 g (3 pieces) fruit biscuits (Verkade, Zaandam, 
The Netherlands) per day. The subjects received the products in daily packages, 
which they had to consume throughout the day. Total energy contents of the dairy 
and control products were similar (Table 4.1). At the end of each treatment period, 
energy and nutrient intakes during the previous 4 weeks were estimated using a va-
lidated food frequency questionnaire [112]. Subjects had to record all signs of ill-
ness, use of medication, or deviations from the study protocol in a diary.  
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Table 4.1. Composition of dairy and control products. 
 Dairy Control 
 Product 
content 
% of subjects’ 
daily intake 
Product 
content 
% of subjects’ 
daily intake 
Energy (MJ) 1.5 16.3 ± 3.7 1.7 18.9 ± 3.4 
Protein (g) 24.4 24.0 ± 5.0 2.8 3.3 ± 0.7 
Fat total (g) 9.8 12.8 ± 3.6 3.8 5.5 ± 1.4 
SFA (g) 6.3 21.2 ± 5.9 1.6 6.6 ± 2.1 
MUFA (g) 2.4 10.4 ± 3.7 0  -  
PUFA (g) 0.3 2.0 ± 0.5 0.6 3.9 ± 1.0 
TFA (g) 0.4 23.6 ± 14.5 0  -  
Carbohydrates (g) 39.7 15.7 ± 4.3 85.0 30.6 ± 6.0 
Mono- and disaccharides (g) 39.2 30.4 ± 9.9 70.2 45.1 ± 11.0 
Fiber (g) 0 -  2.7 12.1 ± 3.5 
Cholesterol (mg) 27.5 13.7 ± 3.7 0  -  
Calcium (mg) 800 53.2 ± 9.2 75 9.0 ± 3.1 
All values are means ± SD. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyun-
saturated fatty acids; TFA, trans fatty acids. 
Blood sampling and analyses 
At the start of each period and after 4, 7, and 8 weeks, blood samples were taken 
after an overnight fast. Subjects were not allowed to use alcohol during the pre-
vious day or to smoke on the morning before blood sampling. Venous blood was 
drawn into EDTA tubes using a Vacutainer system (Becton Dickinson, Franklin Lakes, 
USA). After sampling, the tubes were kept on ice and centrifuged within one hour 
after venipuncture at 2500g for 30 min at 4°C, and plasma samples were snap-
frozen in liquid nitrogen and stored at -80°C. 
 Samples of weeks 7 and 8 were pooled before analysis. Plasma concentrations 
of TNF-α and IL-6 were determined using ELISA kits (R&D Systems, Abingdon, UK). 
ELISA kits were also used for the measurement of plasma concentrations of Mono-
cyte Chemoattractant Protein-1 (MCP-1) (Human MCP-1 Ultra-Sensitive Kit), soluble 
TNF-α Receptor (s-TNFR) 1 and 2 (Human TNFR1 and TNFR2 Ultra-Sensitive Kit), 
Intracellular Adhesion Molecule-1 (ICAM-1), and Vascular Cell Adhesion Molecule-1 
(VCAM-1) (Human Vascular Injury II Kit, Meso Scale Discovery, Gaithersburg, MD, 
USA). TNF-α index was calculated as [TNF-α] / [s-TNFR2] [131]. To test subjects’ 
compliance, plasma concentrations of 1,25-dihydroxy vitamin D3 (1,25-(OH)2-D3) 
were determined by ELISA (Immunodiagnostic Systems, Boldon, UK). 1,25-(OH)2-D3 
concentrations are expected to decrease when dietary calcium intake is increased 
[65]. Samples from one subject were analyzed within the same run. All intra- and in-
ter-assay variations were <15%. 
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Statistics 
The statistical power to detect a true difference of 10% was more than 80% for all 
parameters, except for IL-6. All statistical analyses were performed using SPSS 16.0 
for Macintosh OS X (SPSS, Chicago, USA). Differences in endpoints between dairy 
and control periods, which were normally distributed as indicated by the Shapiro-
Wilk test, were examined by paired t-test analysis. Values are presented as means ± 
standard deviations and as absolute changes (95% confidence interval (CI) for abso-
lute change). A P-value <0.05 (two-sided) was considered as statistically significant. 
The presence of time and sequence effects was tested as described [116]. Also, dif-
ferences between men and women were tested by an unpaired t-test. 
Results 
Subjects, dietary intakes and compliance  
Subjects were 49.5 ± 13.2 y old and their BMI was 32.0 ± 3.8 kg/m
2
. Mean body 
weight at the end of the intervention periods was not different between the dairy 
diet (91.1 ± 13.1 kg) and the control diet (91.3 ± 13.5 kg; P=0.561). The mean dietary 
intakes in the dairy and control periods were estimated from food frequency ques-
tionnaires. The exchange of low-fat dairy products for the carbohydrate-rich control 
products was reflected in the changes in the intakes of protein (19.9 ± 3.2 vs. 16.0 ± 
2.4 En%), total fat (33.1 ± 4.7 vs. 29.9 ± 4.9 En%), saturated fatty acids (12.8 ± 2.1 vs. 
10.7 ± 2.1 En%), monounsaturated fatty acids (10.3 ± 1.9 vs. 9.2 ± 1.9 En%), carbo-
hydrates (45.9 ± 6.1 vs. 52.5 ± 5.8 En%), fibre (2.3 ± 0.6 vs. 2.6 ± 0.7 g/MJ), choles-
terol (23.3 ± 5.6 vs. 19.7 ± 4.5 mg/MJ), and calcium (1550 ± 281 vs. 931 ± 291 mg) 
(all P<0.05). Total energy intake was not different between the dairy and control in-
terventions. Plasma concentrations of 1,25-(OH)2-D3 were significantly decreased at 
the end of the dairy period (119 ± 30 pmol/L) compared with the control period 
(128 ± 37 pmol/L; P=0.034). 
Inflammatory markers and adhesion molecules 
Plasma IL-6 concentrations were not different between the dairy and control period 
(Table 4.2), while concentrations of TNF-α tended to be lower after dairy consump-
tion (P=0.070). Concentrations of s-TNFR-1 tended to be higher after dairy con-
sumption (P=0.062), and s-TNFR-2 concentrations were significantly higher after the 
dairy diet than after the control diet (P=0.020). Although the change in s-TNFR-1 
was not statistically significant, it was correlated with the change in s-TNFR-2 (Pear-
son r=0.692, P<0.001). Calculated TNF-α index was lower after dairy than after con-
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trol (P=0.015). Dairy consumption had no effect on plasma concentrations of MCP-
1, ICAM-1 and VCAM-1. No time or sequence effects were present and responses 
did not differ between men and women. 
 
Table 4.2. Effects of dairy consumption on inflammatory markers and adhesion molecules. 
 Dairy Control Change 95% CI P-
value 
s-TNFR-1 
 (pg/mL) 
3729 ± 853 3619 ± 769 110.4 ± 338.4 -5.77 to 226.7 0.062 
s-TNFR-2 
 (pg/mL) 
4367 ± 1359 4140 ± 1122 227.0 ± 549.0 38.4 to 415.6 0.020 
TNF-α 
 (pg/mL) 
2.32 ± 0.64 2.48 ± 0.76 -0.16 ± 0.50 -0.33 to 0.01 0.070 
TNF-α 
 index 
0.00057 
± 0.00021 
0.00062 
± 0.00020 
-0.000053 
± 0.00012 
-0.000096 
to -0.000011 
0.015 
IL-6  
 (pg/mL) 
3.01 ± 3.47 3.05 ± 3.24 -0.04 ± 1.46 -0.54 to 0.46 0.875 
MCP-1 
 (pg/mL) 
291.1 ± 68.5 289.7 ± 66.5 1.45 ± 29.4 -8.64 to 11.5 0.772 
ICAM-1 
 (ng/mL) 
280.5 ± 78.6 286.9 ± 86.6 -6.43 ± 27.7 -15.9 to 3.07 0.178 
VCAM-1 
 (ng/mL) 
447.7 ± 110.0 436.1 ± 103.1 11.6 ± 76.4 -14.7 to 37.8 0.377 
s-TNFR, soluble TNF-α receptor; MCP-1, monocyte chemoattractant protein-1; ICAM-1, intracellular ad-
hesion molecule-1; VCAM-1, vascular cell adhesion molecule-1. 
Discussion 
Data from this study indicate that low-fat dairy consumption for 8 weeks may affect 
markers reflecting low-grade systemic inflammation in overweight and obese sub-
jects. We found a significant increase in plasma s-TNFR-2 concentrations after low-
fat dairy consumption, while there was a trend towards higher s-TNFR-1 and lower 
TNF-α concentrations. Subjects’ compliance was confirmed by the expected de-
crease in plasma concentrations of 1,25-(OH)2-D3.  
 Elevated concentrations of TNF-α have been found to relate to obesity, insulin 
resistance and the metabolic syndrome [34, 132]. An enlarged adipose tissue mass 
increases the production of TNF-α, which may in turn cause insulin resistance by af-
fecting signalling pathways in different organs. Although animal studies have estab-
lished TNF-α as a link between obesity and insulin resistance [133, 134], evidence 
from human studies is less conclusive. Reduced insulin-induced glucose uptake after 
TNF-α infusion has been shown in healthy subjects [135]. Further, the use of anti-
TNF-α drugs in inflammatory conditions induced a concomitant improvement in in-
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sulin sensitivity in several human trials [136-138], whereas no beneficial effects of 
TNF-α neutralization on insulin sensitivity were found in other studies [139-141]. 
Further, the function of soluble TNF-α receptors (s-TNFR-1 and s-TNFR-2) is not yet 
fully understood. Elevated concentrations of soluble TNF-α receptors have been as-
sociated with obesity [142, 143] and weight loss has been found to decrease TNF-α 
and increase s-TNFR concentrations [144]. The membrane-bound forms of the two 
TNF-α receptors activate different intracellular pathways upon TNF-α binding, facili-
tating its physiological effects [145]. Circulating TNF-α receptors, on the contrary, 
are able to compete for TNF-α binding with the cell surface receptors and have 
been proposed to function as inhibitors of TNF-α action. Through the formation of 
high affinity complexes and subsequent reduction of the amount of active TNF-α, 
they might protect against the potentially harmful effects of TNF-α [146, 147]. Illu-
strative, a dimeric recombinant form of s-TNFR-2, known as etanercept, is often 
used in inflammatory conditions such as rheumatoid arthritis and psoriasis and has 
been shown to improve inflammatory conditions in patients with the metabolic 
syndrome [139]. Our data show increased concentrations of s-TNFR-2 after low-fat 
dairy consumption, which might imply lower biological availability of TNF-α protein. 
In fact, when we calculated the TNF-α index, a measure for biologically available 
TNF-α [131], we found reduced numbers after the dairy intervention. The effect of 
dairy products on the TNF-α pathway in human subjects has, thus far, not been ex-
plored. Experiments in mice have indicated that calcium and dairy products may re-
duce TNF-α production [111, 148], but effects in humans have not been studied be-
fore. Our results might imply beneficial effects of low-fat dairy consumption on TNF-
α action, but the precise consequences of these observations have to be further ex-
amined. It may be interesting for future research to study the effects of dairy intake 
on the activity, besides the concentration, of TNF-α and related parameters, since 
signalling from the TNF-α receptor has been found to be modulated by calcium-
dependent proteins [149]. 
 Other inflammatory markers and adhesion molecules, however, were not af-
fected by dairy consumption. Studies addressing the effects of dairy products or its 
constituents on inflammation or endothelial function are scarce. Wennersberg et al. 
studied the effects of 6-month dairy consumption in overweight men and women 
and found no differences in markers of inflammation (IL-6, CRP, TNF-α) and endo-
thelial dysfunction (E-selectin, Von Willebrand Factor), except for a decrease in 
VCAM-1, which was only present in women [150]. Zemel et al. reported reductions 
in plasma TNF-α and IL-6, and an increase in plasma adiponectin in mice fed a high-
dairy diet [111]. They also evaluated samples from obese men and women who fol-
lowed a high-dairy eucaloric or hypocaloric diet for four weeks. Compared with a 
low-dairy group, they observed decreased concentrations of CRP and increased 
concentrations of adiponectin after the high-dairy diets. Although the effects of an 
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improved body composition cannot be fully excluded, the authors also suggest a 
role for the suppression of 1,25-(OH)2-D3. In previous in vitro experiments, they 
showed that 1,25-(OH)2-D3 stimulated TNF-α and IL-6 expression [151, 152]. On the 
contrary, other in vitro and animal studies provide evidence that 1,25-(OH)2-D3 has 
anti-inflammatory properties [153-155]. In our study, concentrations of 1,25-(OH)2-
D3 were measured as marker of dietary compliance and were indeed reduced by 
dairy consumption, but its role in the modulation of the TNF-α pathway remains to 
be elucidated. Recently, Zemel et al. showed that a eucaloric dairy-rich diet reduced 
inflammatory markers (IL-6, TNF-α, MCP-1) and increased adiponectin in over-
weight and obese subjects when compared with a soy-rich diet, in the absence of 
changes in adiposity [156]. Effects were already present after 7 days of intervention, 
and were even more pronounced after 28 days. Our results now suggest that effects 
on TNF-α related parameters are still present after an 8-week intervention period. 
However, whether these changes are enduring for a longer period needs further 
study.  Further, unlike Zemel et al. [156], we observed no effects on IL-6 an MCP-1 
for which we have no obvious explanation. 
 Taken together, our results indicate that low-fat dairy consumption for 8 weeks, 
compared with carbohydrate-rich product consumption, may modulate TNF-α sig-
nalling by increasing s-TNFR-2, but does not affect other markers of low-grade sys-
temic inflammation and endothelial function in overweight and obese subjects.
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ABSTRACT 
 
Increased postprandial hyperlipidemia and hyperglycemia are positively asso-
ciated with cardiovascular disease. Several studies have suggested that two 
major milk constituents, casein and calcium, favourably affect postprandial li-
pid responses. However, the effects of milk on postprandial responses are un-
known. In this study, we investigated the effects of addition of milk to a high-
fat meal on lipid and glucose responses in overweight and obese men. To iden-
tify the constituent responsible for the effects, we also studied responses to 
calcium and protein. Sixteen male subjects (BMI >27 kg/m
2
) participated in 4 
postprandial tests. They consumed a breakfast (44 g of fat) plus a drink: a con-
trol, calcium, or protein drink, or low-fat milk (500 mL). Blood samples were 
taken before the meals and at regular time points during 6 h thereafter. The 
incremental area under the curve (iAUC) for serum triacylglycerol (TAG) was 
increased by 25% after the milk meal (P=0.024) and by 38% after the protein 
meal (P=0.001) compared with the control meal. Glucose iAUC was not differ-
ent between the test meals, but the maximal increase in plasma glucose was 
reduced by 13% in the milk intervention (P=0.030) and by 20% in the protein 
intervention (P=0.001). The milk meal increased insulin iAUC by 35% (P=0.001). 
Free fatty acid concentrations were not different between test meals. Our re-
sults indicate that the addition of milk to a fat-containing meal increases the 
postprandial iAUC for insulin and TAG, but decrease the maximal increase in 
glucose. The protein fraction seems to be the main determinant, while calcium 
has no effects on these parameters. 
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Introduction 
Postprandial hyperlipidemia and hyperglycemia are strongly associated with cardio-
vascular disease (CVD) [157, 158]. In fact, postprandial changes in plasma triacylgly-
cerol (TAG) and glucose concentrations might be more strongly associated with CVD 
risk than their fasting concentrations [159-161]. As people in the Western world are 
in a non-fasting state for most of the day, these are important findings. Fasting glu-
cose concentrations have found to be predictive of postmeal glucose excursions 
[162] and high concentrations of fasting TAG are often predictive of postprandial 
hyperlipidemia [163, 164], which is therefore frequently seen in patients with the 
metabolic syndrome [165]. 
 The macronutrient composition of a meal is an important determinant of the 
postprandial response. High-fat meals have been found to increase TAG concentra-
tions [166, 167], impair endothelial function [168-170], and increase markers of in-
flammation and endothelial dysfunction [171, 172]. However, Westphal et al. have 
shown that adding carbohydrates (glucose) to a high-fat meal resulted in a delay 
and reduction of postprandial lipidemia [173]. Casein had an even stronger effect: 
chylomicron responses were further reduced and delayed, which could not be ex-
plained by gastric emptying time. Further, concentrations of C-peptide and insulin 
were elevated during the post-absorptive phase (4-8 h) after the casein-containing 
meals. Whether dairy products have comparable effects on postprandial metabol-
ism, as has milk protein alone, is not known. Furthermore, it has been reported that 
increased calcium intake from dairy products reduced chylomicron TAG concentra-
tions after a meal [57]. However, the effects of calcium on other postprandial res-
ponses have not been studied before. In this study, we therefore investigated ef-
fects of addition of low-fat milk to a high-fat breakfast on postprandial lipid and 
carbohydrate metabolism in overweight and obese subjects. To evaluate which of 
the dairy components may be responsible for the effects, we also studied the post-
prandial responses of milk protein and calcium, two major milk constituents. 
Methods 
Study population 
Subjects were recruited in Maastricht and surroundings by advertisements in local 
newspapers and posters in hospital and university buildings. People who were in-
terested to participate were informed about the purposes and requirements of the 
study and all gave their written informed consent before they entered the screening 
procedure. The study was approved by the Medical Ethical Committee of Maastricht 
University Medical Centre+ and was registered at ClinicalTrials.gov as NCT00917878. 
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Subjects were invited for the screening procedure when they met the following in-
clusion criteria: male; 18-70 y; non-smoking; BMI >27 kg/m
2
; no active cardiovascu-
lar disease, familial hyperlipidemia, inflammatory diseases, or other medical condi-
tions that might interfere with the study outcomes; no abuse of alcohol or drugs; 
stable body weight during the past 3 months. During two screening visits, body 
weight, height and blood pressure were measured and a fasting blood sample was 
taken to determine serum lipid and lipoprotein concentrations. Sixteen subjects 
were enrolled in the study (Table 5.1). They were asked not to change their dietary 
habits, use of alcohol, and level of physical exercise during the study. They were also 
requested to record any signs of illness, use of medication or other important de-
tails during the study period in a diary. All subjects completed the study. 
 
Study design and intervention 
The study consisted of four test days, which were separated by a washout period of 
at least 3 days. On each test day, subjects received a different test meal in rando-
mized order, and participated in a postprandial test. Subjects were asked not to per-
form any strenuous physical exercise and not to consume alcohol on the day before 
testing. They were also asked to refrain from high-fat foods on the day prior to the 
test days. After an overnight fast, subjects arrived at the university by public trans-
port or car. An intravenous cannula (Venfon®; Becton Dickinson, Franklin Lakes, 
USA) was inserted in an antecubital vein and blood samples were collected for anal-
ysis of fasting concentrations of metabolic risk markers. Subjects were then re-
quested to consume one of the test meals within 10 minutes. Subsequent blood 
samples were drawn at 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 min after 
meal consumption. Subjects were allowed to drink water (250 mL) directly after the 
T=120 and T=240 blood collections. The test meals consisted of 168 g butter cake 
and 500 mL of one of four drinks (Table 5.2). In the milk intervention, subjects con-
sumed skimmed milk (0% fat; Campina, Woerden, The Netherlands). All drinks con-
tained an equal amount of lactose (DMV International, Veghel, The Netherlands). 
The protein drink contained the same amount of protein (REFIT Total Milk Protein; 
DMV International) as the milk, while the calcium content (Lactoval; DMV Interna-
tional) of the calcium and protein drinks was equal to that of the milk. The amino 
acid composition of all meals is given in Table 5.3. 
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Table 5.1. Characteristics of the subjects. 
  
Age (y) 49.8 ± 15.5 
BMI (kg/m
2
) 31.2 ± 3.6 
Weight (kg) 101.5 ± 10.6 
Height (m) 180.8 ± 4.6 
Systolic blood pressure (mmHg) 129.1 ± 12.3 
Diastolic blood pressure (mmHg) 86.0 ± 8.1 
Glucose (mmol/L) 5.66 ± 0.35 
Insulin (mU/L) 23.0 ± 10.2 
Total cholesterol (mmol/L) 5.58 ± 0.87 
HDL cholesterol (mmol/L) 1.23 ± 0.27 
LDL cholesterol (mmol/L) 3.57 ± 0.70 
Triacylglycerol (mmol/L) 1.71 ± 0.62 
All values are means ± SD. 
 
 
Table 5.2. Composition of the test meals. 
 Control Calcium Protein Milk 
Products Butter cake 168 g 
Water 500 mL 
Lactose 29 g 
Butter cake 168 g 
Water 500 mL 
Lactose 29 g 
Calcium 2.3 g 
Butter cake 168 g 
Water 500 mL 
Lactose 29 g 
Milk protein 23.4 g 
Calcium 1.3 g 
Butter cake 168 g 
Milk 500 mL 
Energy (kcal) 864 864 948 948 
Protein (g) 8 8 29 29 
Carbohydrates (g) 
Of which:       
Mono/disaccharides (g) 
Lactose (g) 
109 
 
74 
30 
109 
 
74 
30 
109 
 
74 
30 
109 
 
74 
30 
Fat (g) 44 44 44 44 
Calcium (mg) 49 699 703 697 
Phosphorus (mg) 100 353 407 600 
Blood sampling and analyses 
Venous blood was sampled using a Vacutainer system (Becton Dickinson). Blood 
was drawn into serum separator tubes for the analysis of lipids and lipoproteins. Af-
ter clotting at room temperature for at least 30 min, serum was obtained by centri-
fugation at 1300 g for 15 min at room temperature and stored at -80°C. Further, 
blood was sampled into EDTA tubes for the analysis of insulin and free fatty acids 
(FFA) concentrations and sodium fluoride (NaF) tubes were used for analysis of 
plasma glucose and amino acid concentrations. EDTA and NaF tubes were kept on 
ice until centrifugation at 1300 g for 15 min at 4°C. Plasma samples were snap-
frozen in liquid nitrogen and stored at -80°C. 
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Table 5.3. Amino acid composition of the test meals. 
 Control Calcium Protein Milk 
Cysteine (g) 0.17 0.17 0.30 0.32 
Methionine (g) 0.12 0.12 0.70 0.67 
Aspartic acid (g) 0.32 0.32 1.89 1.87 
Threonine (g) 0.24 0.24 1.18 1.09 
Serine (g) 0.35 0.35 1.52 1.45 
Glutamic acid (g) 2.25 2.25 6.77 6.50 
Proline (g) 0.79 0.79 2.94 2.74 
Glycine (g) 0.25 0.25 0.64 0.60 
Alanine (g) 0.22 0.22 0.88 0.87 
Valine (g) 0.30 0.30 1.66 1.55 
Isoleucine (g) 0.25 0.25 1.34 1.30 
Leucine (g) 0.50 0.50 2.49 2.50 
Tyrosine (g) 0.22 0.22 1.33 1.22 
Phenylalanine (g) 0.34 0.34 1.35 1.29 
Histidine (g) 0.15 0.15 0.72 0.65 
Lysine (g) 0.12 0.12 1.76 1.77 
Arginine (g) 0.27 0.27 1.04 1.02 
Tryptophan (g) 0.07 0.07 0.34 0.35 
Total AA (g) 6.93 6.93 28.85 27.76 
Essential AA (g) 1.94 1.94 10.83 10.52 
Non-essential AA (g) 4.99 4.99 18.02 17.24 
Essential AA: Methionine, Threonine, Valine, Isoleucine, Leucine, Phenylalanine, Lysine, Tryptophan. 
 
 
Baseline serum samples were analyzed for concentrations of total cholesterol 
(CHOD-PAP method; Roche, Basel, Switzerland) and HDL-cholesterol (precipitation 
method; Roche). LDL-cholesterol concentrations were calculated using the Friede-
wald equation [113]. Concentrations of TAG, with correction for free glycerol, were 
determined in serum samples from T=0, 60, 120, 180, 240, 300, and 360 min (GPO 
Trinder; Sigma Diagnostics, St. Louis, USA). FFA were analysed by an enzymatic as-
say (NEFA kit; WAKO, Neuss, Germany) in plasma samples from T=0, 60, 120, 240, 
and 360 min. Glucose concentrations (Horiba ABX, Monpellier, France) and insulin 
concentrations (radioimmunoassay, Millipore, Billerica, USA) were measured in 
plasma samples from T=0, 15, 30, 45, 60, 90, 120, 240, and 360 min. Plasma amino 
acid concentrations were determined at T=0, 60, and 120 min as described else-
where [174]. 
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Statistics 
Data are presented as means ± SD. To evaluate the overall response of total TAG, 
glucose, and insulin during the 6-h postprandial period, the incremental areas under 
the postprandial curve (iAUC) or decremental areas under the curve (dAUC) were 
calculated using the trapezoidal rule. Maximal changes were calculated by subtract-
ing baseline values from the maximal or minimal value. All statistical analyses were 
performed using SPSS 16.0 for Macintosh OS X package (SPSS, Chicago, USA). Differ-
ences in iAUC and maximal changes between the test meals were tested for signi-
ficance by univariate ANOVA followed by Bonferroni’s correction for multiple com-
parisons. A P-value <0.05 was considered as statistically significant. 
Results 
Triacylglycerol 
Serum TAG concentrations during the postprandial phase after ingestion of the test 
meals are presented in Figure 5.1. Compared with baseline values, all test meals in-
creased serum TAG concentrations, which reached peak concentrations after 180 
min. After all meals, serum TAG concentrations had not returned to baseline values 
after 360 min. iAUC and maximal increases are shown in Table 5.4. Addition of pro-
tein or milk to the meal significantly increased the iAUC by 38% (P=0.001) and 25% 
(P=0.024), respectively, compared with the control meal. During the early phase (0-
180 min), no differences in iAUC between the milk and control meal were present 
(P=0.409), while in the late phase (180-360 min) the iAUC was increased after the 
milk meal (P=0.016). The protein meal increased the iAUC in the early (P=0.003) as 
well as the late phase (P=0.007). The iAUC after the calcium meal was not different 
from control (P=0.275). The maximal increases in serum TAG were not different be-
tween the four meals (P=0.498). 
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Figure 5.1. Concentrations of triglycerides (TAG), free fatty acids (FFA), glucose and insulin after con-
sumption of a meal providing 40 g of fat and 500 mL of a control, calcium, or protein drink, or low-fat 
milk.  
Glucose and insulin 
Plasma concentrations of glucose and insulin are shown in Figure 5.1. Plasma glu-
cose concentrations were maximally increased 15 min after consumption of the cal-
cium and protein meals and 30 min after consumption of the control and milk 
meals. Concentrations decreased below fasting concentrations after 180 min. The 
maximal increase in plasma glucose from baseline concentrations was significantly 
lowered after the protein meal by 20% (P=0.001), and the iAUC by 34% relative to 
the control meal, but this latter difference did not reach statistical significance 
(P=0.066). The milk intervention reduced the maximal increase in glucose by 13% 
(P=0.030), but did not affect the iAUC. Calcium did not change postprandial glucose 
responses (Table 3).  
 Insulin concentrations were maximal 45 min after consumption of the test 
meals and had returned to baseline concentrations after 360 min. The iAUC was 
significantly higher (35%) after the milk meal than after the control meal (P=0.001). 
No differences in iAUC were observed after the calcium or the protein meal. The 
maximal increases were not statistically different between the four test meals 
(P=0.227). 
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Free fatty acids 
Plasma FFA responses after the four meals are shown in Figure 5.1. FFA concentra-
tions decreased after all meals and reached their minimal value after 120 min. Since 
FFA concentrations dropped below baseline after meal consumption, dAUC instead 
of iAUC were calculated. The dAUC (P=0.218) and the maximal decrease in FFA  
(P=0.114) were not different between the interventions. 
Amino acids 
Plasma concentrations of total, essential and non-essential amino acids after the 4 
meals are given in Table 5.5. After 60 and 120 min, amino acid concentrations were 
significantly increased on the milk and protein meals compared to the control meal. 
Concentrations of the individual amino acids are provided in Table 5.6.  
 
 
 
Table 5.4. Incremental areas under the curves and maximal changes from baseline. 
 Control Calcium Protein Milk P for diet 
effect 
Triacylglycerol 
 iAUC (mmol⋅min/L) 
 Maximal change 
  (mmol/L) 
 
181 ± 71 
0.97 ± 0.41 
 
202 ± 75 
1.12 ± 0.57 
 
249 ± 97* 
1.16 ± 0.44 
 
226 ± 127* 
1.07 ± 0.57 
 
0.007 
0.498 
Glucose 
 iAUC (mmol⋅min/L) 
 Maximal change 
  (mmol/L) 
 
213 ± 124 
3.22 ± 1.10 
 
242 ± 161 
3.15 ± 1.14 
 
155 ± 136 
2.57 ± 1.46* 
 
211 ± 150 
2.79 ± 1.46* 
 
0.051 
0.004 
Insulin 
 iAUC (mU⋅min/L) 
 Maximal change 
  (mU/L) 
 
18794 ± 15189 
179 ± 122 
 
18706 ± 11238 
184 ± 101 
 
17418 ± 13112 
188 ± 110 
 
26691 ± 18608* 
206 ± 116 
 
0.001 
0.227 
FFA 
 dAUC (µmol⋅min/L) 
 Maximal change 
  (µmol/L) 
 
69741 ± 54093 
-319 ± 180 
 
59594 ± 35228 
-290 ± 128 
 
54681 ± 47010 
-274 ± 188 
 
77249 ± 36292 
-356 ± 131 
 
0.218 
0.114 
Values are means ± SD. * Significantly different from control (P<0.05) 
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Table 5.5. Plasma amino acid concentrations after the test meals. 
 Control Calcium Protein Milk P for diet 
effect 
Total AA 
 (µmol/L) 
T0 2493 ± 303 2453 ± 238 2498 ± 310 2479 ± 243 0.890 
T60 2367 ± 320 2342 ± 270 2776 ± 419* 2748 ± 369* <0.001 
T120 2245 ± 340 2202 ± 300 2610 ± 306* 2614 ± 365* <0.001 
EAA  
 (µmol/L) 
T0 844 ± 113 816 ± 100 847 ± 89 835 ± 82 0.553 
T60 741 ± 103 721 ± 88 954 ± 152* 939 ± 121* <0.001 
T120 653 ± 97 639 ± 87 873 ± 103* 877 ± 103* <0.001 
NEAA 
 (µmol/L) 
T0 1649 ± 220 1636 ± 169 1651 ± 251 1644 ± 183 0.990 
T60 1626 ± 250 1622 ± 213 1822 ± 285* 1809 ± 274* <0.001 
T120 1592 ± 267 1562 ± 229 1737 ± 234* 1737 ± 276* <0.001 
Values are means ± SD. AA, amino acids; EAA, essential amino acids (Methionine, Threonine, Valine, Iso-
leucine, Leucine, Phenylalanine, Lysine, Tryptophan); NEAA, non-essential amino acids. * Significantly dif-
ferent from control at corresponding time point (P<0.05). 
 
Table 5.6. Individual amino acid concentrations after the test meals. 
 Control Calcium Protein Milk P for diet 
effect 
Glutamate T0 96.7 ± 34.1 101.3 ± 32.4 96.8 ± 35.8 99.7 ± 29.6 0.667 
T60 91.2 ± 33.0 88.4 ± 32.3 93.7 ± 35.9 89.7 ± 32.0 0.824 
T120 80.2 ± 30.0 87.7 ± 26.9 91.6 ± 27.7 85.4 ± 27.9 0.345 
Aspartic  
acid 
T0 40.2 ± 9.9 38.9 ± 5.2 41.7 ± 9.5 39.4 ± 8.9 0.418 
T60 35.9 ± 9.0 36.2 ± 6.6 46.1 ± 10.8* 46.2 ± 12.0* <0.001 
T120 34.7 ± 8.5 32.3 ± 8.1 42.4 ± 9.9* 42.0 ± 12.4* <0.001 
Serine T0 115.3 ± 20.5 107.7 ± 15.9 117.7 ± 20.8 117.8 ± 19.5 0.790 
T60 106.0 ± 20.0 102.1 ± 16.5 123.2 ± 22.8* 120.5 ± 22.3* <0.001 
T120 99.2 ± 24.4 97.2 ± 16.8 108.1 ± 19.2 110.9 ± 17.8* 0.011 
Glutamine T0 493.5 ± 68.4 489.7 ± 53.6 509.2 ± 76.5 493.2 ± 60.7 0.426 
T60 464.0 ± 75.2 469.2 ± 78.0 508.3 ± 92.3* 511.0 ± 80.0* <0.001 
T120 469.6 ± 71.7 459.9 ± 63.4 494.6 ± 70.4* 500.6 ± 84.6* 0.004 
Histidine T0 74.0 ± 14.7 73.4 ± 11.8 75.1 ± 12.8 74.6 ± 10.8 0.921 
T60 69.5 ± 13.4 69.8 ± 13.3 77.0 ± 15.0* 80.3 ± 12.7* <0.001 
T120 66.4 ± 15.8 66.4 ± 12.4 73.5 ± 13.6* 75.6 ± 12.4* <0.001 
Glycine T0 204.2 ± 44.6 203.7 ± 34.0 215.3 ± 47.4 206.6 ± 39.1 0.350 
T60 185.3 ± 41.6 190.2 ± 41.2 199.9 ± 51.0 196.0 ± 40.4 0.084 
T120 187.2 ± 42.5 184.9 ± 41.1 192.3 ± 42.4 192.3 ± 40.6 0.501 
Threonine T0 128.3 ± 25.6 118.3 ± 14.5 132.8 ± 29.2 119.3 ± 21.0 0.409 
T60 121.9 ± 37.2 119.2 ± 19.7 142.0 ± 31.1* 142.8 ± 27.0* <0.001 
T120 109.4 ± 23.5 110.9 ± 25.1 127.6 ± 29.6* 130.6 ± 27.8* <0.001 
Citrulline T0 32.8 ± 6.6 30.3 ± 5.0 34.3 ± 7.6 33.1 ± 6.1 0.022 
T60 29.8 ± 17.4 25.3 ± 6.1 27.7 ± 7.6 26.9 ± ± 6.9 0.537 
T120 24.8 ± 6.1 25.0 ± 6.6 28.2 ± 6.7* 27.4 ± ± 7.6* 0.001 
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 Control Calcium Protein Milk P for diet 
effect 
Arginine T0 86.0 ± 16.1 82.8 ± 12.3 87.9 ± 17.8 83.8 ± ± 12.7 0.394 
T60 76.5 ± 14.2 77.1 ± 12.6 91.8 ± 22.4* 92.0 ± 17.6* <0.001 
T120 76.0 ± 21.0 71.6 ± 15.6 86.3 ± 20.9* 86.4 ± 18.6* 0.001 
Alanine T0 329.5 ± 84.8 330.8 ± 102.2 335.5 ± 89.1 322.3 ± 99.9 0.921 
T60 414.1 ± 100.2 410.4 ± 82.9 474.2 ± 112.2* 462.2 ± 122.3* 0.001 
T120 418.4 ± 128.1 396.2 ± 96.9 445.8 ± 106.5 440.2 ± 112.7 0.121 
Taurine T0 44.9 ± 6.9 44.4 ± 7.0 43.5 ± 6.8 43.7 ± 8.3 0.754 
T60 35.4 ± ± 5.7 33.2 ± 5.5 35.1 ± 8.1 36.2 ± 8.8 0.196 
T120 32.7 ± 9.2 31.7 ± 5.4 33.4 ± 7.2 33.9 ± 8.0 0.328 
α-Amino 
butyrate 
T0 19.0 ± 5.6 17.7 ± 4.1 17.6 ± 4.9 18.1 ± 4.2 0.716 
T60 16.9 ± 5.5 16.2 ± 3.3 17.7 ± 6.2 18.4 ± 4.9 0.489 
T120 15.6 ± 5.7 15.1 ± 3.2 16.5 ± 4.8 17.5 ± 4.3 0.203 
Tyrosine T0 66.8 ± 13.9 65.1 ± 14.2 66.2 ± 15.3 65.5 ± 14.9 0.820 
T60 59.2 ± 14.2 58.6 ± 14.5 78.4 ± 18.8* 78.8 ± 15.6* <0.001 
T120 52.1 ± 13.7 51.7 ± 13.2 73.0 ± 14.8* 72.6 ± 15.3* <0.001 
Valine T0 232.3 ± 39.6 223.1 ± 28.4 228.0 ± 27.7 223.8 ± 26.3 0.503 
T60 207.7 ± 33.5 197.4 ± 24.9 256.2 ± 40.2* 251.4 ± 24.5* <0.001 
T120 187.4 ± 33.9 178.8 ± 24.4 234.2 ± 26.3* 230.2 ± 22.8* <0.001 
Methionine T0 27.7 ± 7.8 25.9 ± 7.7 26.6 ± 7.9 27.5 ± 5.5 0.625 
T60 23.8 ± 7.6 23.2 ± 6.8 32.2 ± 7.5* 32.1 ± 6.6* <0.001 
T120 18.9 ± 7.1 19.0 ± 6.0 27.4 ± 6.5* 28.2 ± 7.8* <0.001 
Isoleucine T0 73.2 ± 15.0 70.8 ± 16.7 73.1 ± 9.9 73.0 ± 11.1 0.711 
T60 62.7 ± 13.0 58.5 ± 11.7 89.8 ± 17.2* 87.3 ± 9.7* <0.001 
T120 51.1 ± 12.3 49.6 ± 10.9 79.6 ± 11.5* 77.1 ± 9.9* <0.001 
Phenyl-
alanine 
T0 54.2 ± 10.1 53.1 ± 7.4 54.1 ± 7.7 53.9 ± 8.2 0.936 
T60 51.2 ± 6.0 48.8 ± 8.2 61.3 ± 9.1* 60.4 ± 8.2* <0.001 
T120 44.0 ± 6.5 44.5 ± 6.0 58.5 ± 7.9* 57.3 ± 9.9* <0.001 
Tryptophan T0 47.7 ± 12.7 46.1 ± 10.1 45.3 ± 10.3 44.9 ± 9.6 0.635 
T60 42.9 ± 10.3 41.7 ± 9.3 48.2 ± 11.7* 47.3 ± 10.3* 0.009 
T120 37.0 ± 7.9 36.9 ± 6.9 45.7 ± 9.7* 44.1 ± 11.7* <0.001 
Leucine  T0 133.5 ± 26.3 128.4 ± 23.0 135.6 ± 19.8 134.5 ± 17.3 0.238 
T60 113.7 ± 21.3 104.4 ± 20.4 154.7 ± 30.3* 160.0 ± 18.3* <0.001 
T120 91.5 ± 20.1 87.8 ± 17.9 137.2 ± 19.7* 140.1 ± 19.2* <0.001 
Ornithine T0 53.9 ± 12.8 53.4 ± 13.6 58.4 ± 12.8 55.9 ± 11.9 0.248 
T60 50.4 ± 12.9 50.2 ± 12.6 59.9 ± 15.7* 59.8 ± 14.5* <0.001 
T120 48.3 ± 11.6 47.5 ± 13.6 56.2 ± 15.0* 58.9 ± 15.7* <0.001 
Lysine T0 154.6 ± 23.0 155.3 ± 29.3 161.6 ± 19.1 160.8 ± 18.9 0.663 
T60 131.1 ± 19.3 135.6 ± 20.8 177.3 ± 38.0* 180.8 ± 29.2* <0.001 
T120 121.9 ± 14.1 120.7 ± 20.6 167.1 ± 30.5* 175.7 ± 27.4* <0.001 
Values are means ± SD. *Significantly different from control at corresponding time point (P<0.05). 
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Discussion 
The aim of this study was to investigate the effects of milk and of protein and cal-
cium, two major milk constituents, on postprandial lipid and glucose metabolism. 
We found that protein increased the iAUC for TAG, but decreased the maximal in-
crease in glucose. Further, the iAUC for insulin and TAG were increased and the 
maximal glucose response decreased when milk was added to the meal. The addi-
tion of calcium to the fat-containing meal had no effects on these parameters.  
 Results from other studies on postprandial effects of protein on TAG responses 
are not conclusive. Our finding that the addition of milk or milk protein increased 
the iAUC for TAG is in contrast with the observations of Westphal et al., who found 
in normal-weight men and women no change in this parameter when casein was 
added to a high-fat, carbohydrate-containing meal [173]. In fact, the iAUC for the 
chylomicron fraction was even decreased. In a second study, casein and soy also re-
duced serum TAG concentrations at the early time points, when added to a high-fat 
meal containing virtually no carbohydrates [175]. However, in that study no iAUC 
values were given and no difference was made between chylomicron, VLDL, and to-
tal serum TAG. The amount of protein given to the subjects was higher than in our 
study (around 50 g), but also the amount of fat (around 70 g). The authors sug-
gested that the decreased chylomicron TAG response [173] resulted from a delayed 
gastric emptying and from the increased insulin concentrations. Insulin activates li-
poprotein lipase (LPL), which might degrade chylomicron TAG more rapidly [176]. It 
has, however, been described that the responsiveness of LPL in adipose tissue to in-
sulin and meals is diminished in obesity [26]. As the subjects in our study were all 
overweight or obese, in contrast to those in the trials of Westphal et al. [173, 175], 
it can be speculated that this might at least partly explain the different findings. 
However, in an other trial in overweight, type 2 diabetic, subjects, Brader et al. did 
find a decrease in TAG after casein consumption, but only in combination with car-
bohydrate consumption [177]. Cohen observed no effects of casein addition (23 g) 
on postprandial lipidemia after a high-fat (40 g) meal in normal-weight men and 
women [178]. One study has reported increased TAG concentrations after fat and 
casein consumption in healthy male subjects [179]. However, since only 4 out of 6 
subjects showed increased postprandial lipidemia after protein ingestion and results 
were not statistically analyzed, the findings of this study are difficult to interpret. 
The protein we used was a total milk protein, containing the total fraction of cow’s 
milk (mainly casein and whey), and thus somewhat different from the protein used 
by Westphal et al. [173]. However, they obtained comparable results for casein and 
soy, suggesting that the type of protein is of less importance [175]. We provided the 
protein on top of the meals, resulting in a higher energy intake in the protein and 
milk meals. However, it is not likely that a higher energy intake per se will increase 
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postprandial TAG concentrations. For example, when extra energy is added to a fat-
rich meal in the form of glucose, the TAG response may even be reduced [180, 181].  
 The serum TAG response was not affected by the addition of calcium to the 
meal. Lorenzen et al. found that calcium from dairy products (350 or 800 mg), but 
not a calcium carbonate supplement (850 mg), reduced the iAUC for chylomicron 
TAG after a fat load [57]. The authors suggested that this decrease may be due to a 
reduction in fat absorption, since a number of studies have shown that calcium in-
take increases faecal fat excretion, probably through the binding of calcium to fatty 
acids, mainly saturated fatty acids, in the intestine [51, 53, 55, 182]. However, no 
differences in total plasma TAG were observed, which is in line with our findings. Ef-
fects on fat absorption can, however, not be fully excluded as the effect on chylomi-
cron TAG may have been too small to be detected in the total TAG fraction, or coun-
teracted by an increase in VLDL. It should be noted that the calcium supplement 
used in our trial was derived from a dairy source, as we wanted to investigate 
whether calcium could be the dairy constituent responsible for the effects of milk, if 
any.  
 We further observed a 35% increase in the insulin response after the milk meal, 
but no increase after the protein meal. Protein, especially in combination with car-
bohydrates, has been reported to induce insulin secretion already in 1966 [183]. 
Van Loon et al. confirmed the insulinotropic potential of various proteins, hydroly-
sates, and free amino acids in combination with carbohydrates in a series of studies 
in healthy young subjects [184-186]. One of the most insulinotropic amino acids was 
leucine, which is highly present in milk protein. In addition, it has been suggested 
that protein may decrease hepatic insulin extraction from the circulation. Addition 
of whey protein to a meal resulted in elevated postprandial insulin concentrations, 
while C-peptide levels were unaffected [187]. However, Westphal et al. did find in-
creased C-peptide concentrations after casein consumption, indicating an increased 
insulin production [173]. Our observation that the insulin response was elevated by 
the milk meal, but not by the protein meal, is unexpected, since the protein con-
tent, the type of protein, the amino acid composition, and the calcium and lactose 
content were exactly the same in both drinks. Further, changes in plasma concen-
trations of amino acids were comparable after the milk and protein meal. So, there 
should be an additional factor in milk that influences either the secretion or the 
clearance of insulin. 
 The iAUC for glucose were not different between the meals, but the peak 
change was decreased by the milk and protein meal, while it was unaffected by the 
calcium meal. So, we observed a reduction in the maximal glucose concentration, 
while the insulin response was not changed after the protein meal. A number of 
amino acids, including lysine [188], proline [189], glycine [190], and arginine [191], 
have been found to attenuate plasma glucose levels when ingested in combination 
with carbohydrates, without elevating insulin concentrations. However, other 
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amino acids, such as leucine [192] and phenylalanine [193], have been shown to 
cause a reduction in plasma glucose and a concurrent increase in insulin secretion. 
The increased insulin response after the milk could explain the lower peak glucose 
levels. The increased insulin levels after the milk diet, however, did not affect FFA 
concentrations. This is in contrast to the reduced FFA concentrations observed by 
Westphal et al. [173, 175], who contribute this to the increased insulin response. 
However, Brader et al. did not find significant differences in FFA AUC, in spite of an 
increase in insulin after casein consumption [177]. 
 In conclusion, our results indicate that adding milk to a fat-containing meal may 
enhance the TAG and insulin response and may reduce maximal glucose levels. The 
protein fraction of the milk seems to be mainly accountable for the effects. The cal-
cium content does not change the postprandial responses after a fat meal and does 
not seem to be the major component responsible for the effects of milk.  
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ABSTRACT 
 
Hepatic insulin resistance and inflammatory cytokine production contribute to 
the manifestation of the metabolic syndrome. As amino acids have been impli-
cated in modulating insulin signalling and inflammation, we have investigated 
the effects of glutamine, leucine and proline on markers of inflammation and 
insulin sensitivity in HepG2 liver cells. Cells were incubated with IL-1β (5 
ng/mL) to stimulate IL-8 production. After 24 h, glutamine inhibited IL-8 pro-
duction significantly (P<0.05) at 2, 5 and 10 mM (to 82%, 73% and 72% of con-
trol), while leucine reduced IL-8 production significantly only at 10 mM (66%) 
and proline at 5 and 10 mM (71% and 52%). Glutamine, leucine and proline all 
reduced NF-κB activity after 3 h of IL-1β stimulation at 2, 5, and 10 mM 
(P<0.001). Insulin-induced (1 nM) Akt phosphorylation was reduced in cells 
treated with tumour necrosis factor-α (10 ng/mL) for 24 h, but was partly res-
tored by simultaneous incubation with glutamine, leucine and proline (25 
mM). Phosphorylation of glycogen synthase kinase-3β was unaffected by insu-
lin stimulation and amino acid treatment. Our results indicate that glutamine, 
leucine and proline attenuate IL-8 production, probably through inhibition of 
NF-κB, and that they increase Akt phosphorylation in HepG2 cells. 
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Introduction 
The metabolic syndrome covers numerous factors that enhance the risk for cardi-
ovascular disease and type 2 diabetes mellitus. These risk factors, including dyslipi-
demia, insulin resistance, hypertension, a prothrombotic state, and chronic inflam-
mation, result from a complex interplay between multiple tissues in the body [13]. 
Of these tissues, the liver is one of the most important organs involved, because of 
its central role in lipid and glucose homeostasis. In fact, a strong correlation exists 
between obesity and non-alcoholic fatty liver disease (NAFLD), which is considered 
to be a hepatic manifestation of the metabolic syndrome [194]. An increased flux of 
plasma free fatty acids and elevated levels of inflammatory cytokines, both often 
the result of an enlarged fat mass, may cause hepatic insulin resistance and subse-
quent disturbances in hepatic fat and glucose handling. In addition, the inflammato-
ry response of the liver itself is often enhanced in metabolic diseases and results in 
increased production of pro-inflammatory cytokines and acute phase proteins [34].  
 Diet is one of the environmental factors that play a part in the development of 
these metabolic disturbances. Amino acids are one group of nutrients that may be 
of interest in their prevention and treatment. Amino acids, as provided by proteins, 
are an important component of the western diet and form 10 to 15 energy percent 
of the total food intake. They are highly abundant in dairy, meat, and other high-
protein foods. Several amino acids have been reported to modulate the inflamma-
tory response. For example, glutamine decreased the release of the proinflammato-
ry cytokines IL-8 and IL-6 in human intestinal cells in vitro [195-197]. Another amino 
acid, histidine, was also found to inhibit the production of IL-8 in intestinal epithelial 
cells [198]. In addition, some studies indicated that amino acids might modulate in-
sulin action in isolated adipocytes [199, 200]. In rat heart tissue, amino acid sup-
plementation was found to upregulate glucose transporter GLUT-4 [201]. Branched 
chain amino acids (BCAA) were reported to increase glucose uptake in skeletal mus-
cle and hepatocytes in rodents [202, 203]. Moreover, BCAA-enriched supplements 
have been found to improve insulin resistance in patients with chronic liver disease 
[204]. These findings may implicate a role for amino acids in the modulation of insu-
lin resistance as well. Furthermore, dairy products, which are a rich source of pro-
teins, have been associated with a lower prevalence or incidence of the metabolic 
syndrome and its components [36, 37, 39, 43, 44]. It is possible that the amino acids 
derived from dairy proteins are (partly) responsible for any possible positive effects 
of dairy products on metabolic abnormalities.  
 In the present study, we therefore investigated the effects of glutamine, leucine 
and proline, the most abundant amino acids in dairy products [205], on markers re-
flecting inflammation and insulin signalling in a liver cell model.  
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Materials and methods 
Cell culture 
The liver cell line HepG2 was kindly provided by Dr. S. Braesch-Andersen (Mabtech, 
Nacka Strand, Sweden). Cells were cultured in Minimum Essential Medium (MEM) 
containing 10% foetal bovine serum (FBS), 1% sodium pyruvate, 1% L-glutamine, 1% 
non-essential amino acids (NEAA), and 1% penicilline-streptomycine (Invitrogen, 
Carlsbad, USA). The cells were grown under standard culturing conditions at 37°C in 
a 5% CO2 humidified atmosphere.  
Cytokine production assay 
Cells were seeded in 24-well plates (2⋅105 cells/well). After 32 h, the medium was 
replaced by MEM without FBS, L-glutamine and NEAA, and the cells were main-
tained on this medium for 16 h before the start of the experiments. To stimulate cy-
tokine (tumour necrosis factor-α (TNF-α), IL-6, and IL-8) production, the cells were 
incubated for 24 h with IL-1β (5 ng/mL) (Sigma-Aldrich, Saint Louis, USA). In a pilot 
experiment, IL-1β was found to be a stronger inducer of IL-8 production than IL-6 
and TNF-α in these cells. Simultaneously, the amino acids glutamine, leucine, and 
proline (Sigma-Aldrich) were added to the media to final concentrations of 2, 5, and 
10 mM. For all experiments, amino acids were dissolved in MEM. Glucose, also dis-
solved in MEM, was added at the same concentrations to control for energy effects. 
After 24 h, supernatants were collected and stored at -80°C for further analysis. 
During experiments, appearance of the cells was checked microscopically. The pro-
tein content of the samples was determined using the BCA-method according the 
manufacturer’s manual (Pierce, Rockford, USA). 
 The levels of cytokines secreted were measured using ELISA (Hycult biotechnol-
ogy, Uden, The Netherlands). Briefly, 96-well plates were coated with monoclonal 
murine anti-human TNF-α/IL-6/IL-8 antibodies. Recombinant human cytokines were 
used for standard curves. Immobilized cytokines were detected using specific bioti-
nylated rabbit anti-human TNF-α/IL-6/IL-8 polyclonal antibodies, followed by addi-
tion of peroxidase-conjugated streptavidin and tetramethylbenzidine (TMB) sub-
strate. Absorption was measured at 450 nm.  
NF-κB activity assay 
Cells were seeded in 24-wells plates (2⋅105 cells/well) and grown for 24 h. Transient 
transfections were performed using FuGENE® HD Transfection Reagent (Roche, Ba-
sel, Switzerland) according to manufacturer’s instructions. The NF-κB-tk-luciferase 
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vector was kindly provided by Dr. David Gius (National Cancer Institute, Bethesda, 
USA) [206] and was used as a reporter for the activity of nuclear factor-κB (NF-κB). 
Cells were incubated with the FuGENE®-DNA mix for 6 h (0.1 µg pcDNA + 0.1 µg NF-
κB vector per well).  
  Cells were placed on media without FBS, L-glutamine and NEAA for 16 h before 
start of the experiments. Cells were pre-incubated with glutamine, proline, or leu-
cine (2, 5 and 10 mM) for 24 h. Glucose was added at the same concentrations to 
control for energy effects. To induce NF-κB activation, IL-1β (5 ng/mL) was added to 
the media. After 3 h incubation, cells were placed on ice, supernatants were re-
moved and cells were lysed with Reporter Lysis Buffer (Promega, Madison, USA). Ly-
sates were stored at -80°C. NF-κB transcriptional activity was measured using a lu-
minometer (Gomex, 96 microplate luminometer, Promega, Madison, USA) and luci-
ferase assay substrate (Promega, Madison, USA) according to the user manual.  
Akt and GSK-3β phosphorylation assay 
Cells were seeded in 6-well plates (5⋅105 cells/well). After 32 h, the medium was re-
placed by MEM without FBS, L-glutamine and NEAA, and the cells were maintained 
on this medium for 16 h before the start of the experiments. To evaluate the effect 
of amino acids on phosphorylation of Akt, a key protein involved in the signalling 
pathway following insulin stimulation, we first incubated the cells with TNF-α (10 
ng/mL) for 24 h. Prolonged exposure to TNF-α downregulates IRS-1 and prevents 
the occurrence of the insulin signalling cascade, including phosphorylation of Akt, in 
HepG2 cells, creating a situation reflecting insulin resistance [207]. Cells were incu-
bated simultaneously with or without 25 mM of glutamine, leucine and proline. 
Glucose was added at the same concentration to control for energy effects. The 
cells were then exposed to 1 nM of insulin for 5 min to induce Akt phosphorylation. 
Cells were placed on ice, supernatants were removed and cells were washed twice 
with ice cold PBS. Lysates of the cells were obtained by adding 200 µL cold lysis buf-
fer [20 mM Tris (pH 7.4), 150 mM NaCl, 1% Nonidet, 1 mM DTT, 1 mM NaVanadate, 
1 mM PMSF, 10 µg/mL Leupeptin, 1% Aproptenin]. After incubation for 30 min on 
ice, cells were scraped and lysates were cleared by centrifugation and mixed with 
SDS-PAGE sample buffer [125 mM Tris (pH 6.8), 4% sodium SDS, 20% glycerol, 200 
mM DTT, 0.02% Bromphenol Blue], heated for 5 min at 95°C and stored at -20°C.  
 Western blotting was used to visualize the amount of Akt, phosphorylated Akt 
(P-Akt), glycogen synthase kinase 3β (GSK-3β), phosphorylated GSK-3β (P-GSK-3β) 
and β-actin (loading control for equal protein loading) in the lysates. GSK-3β, an en-
zyme that inhibits glycogen synthesis, is inhibited by insulin and is a downstream 
target of P-Akt. Routinely, 30 µg of protein sample was electrophoresed through 
10% SDS-PAGE. Proteins were transferred onto nitrocellulose membranes at 100 
mA overnight at 4°C and visualized by Ponceau S reagent. The blots were blocked 
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with 5% non-fat dry milk/0.05% TBS-Tween20 for 1 h at room temperature. The 
blots were probed with rabbit anti-Akt, anti-P-Akt, anti-GSK-3β, anti-P-GSK-3β, and 
anti-β-actin antibodies (Cell Signaling Technology Inc., Boston, USA) and visualiza-
tion was performed using chemiluminiscence reagent (Pierce Biotechnology, Rock-
ford, USA). 
Statistics 
All statistical analyses were performed using SPSS 16.0 for Macintosh OS X (SPSS, 
Chicago, USA). Data were evaluated using univariate analysis of variance (ANOVA), 
adjusted for multiple comparisons using the Bonferroni’s post hoc test. 
Results 
Effect of amino acids on IL-1β induced cytokine production 
After stimulation with IL-1β, the concentrations of TNF-α and IL-6 were below the 
detection limit (60 pg/mL and 40 pg/mL, respectively) and effects of the amino acids 
on the production of these cytokines could therefore not be evaluated (data not 
shown). Stimulation with IL-1β increased IL-8 production almost 30-fold after 24 h 
of stimulation (P<0.001). After the experiment, cells appearance had not changed, 
as checked microscopically. The protein content was not different between the var-
ious conditions. IL-8 production is given as percentage of control. As shown in Fig-
ure 6.1, incubation with 2 mM, 5 mM and 10 mM glutamine reduced IL-8 produc-
tion significantly to 82%, 73% and 72% of control levels (P=0.009, P=0.001 and 
P=0.001), respectively. IL-8 production was unaffected by incubation with 2 and 5 
mM of leucine (110%, P=0.125 and 92%, P=0.232 respectively), although it was sig-
nificantly reduced by the addition of 10 mM of leucine (66%, P=0.001). Proline did 
not affect IL-8 production at the 2 mM condition (99%, P=0.909), but inhibited pro-
duction of IL-8 to 71% and 52% at 5 and 10 mM (P=0.001 and P<0.001), respectively. 
The addition of 2, 5, and 10 mM glucose did not alter IL-8 production (106%, 103% 
and 104%, respectively, P=1.00). 
Effect of amino acids on IL-1β induced NF-κB activity 
Stimulation of the cells with IL-1β increased NF-κB promoter induced luciferase 
production, as a marker of NF-κB activity, approximately 7-fold (P<0.001). Effects of 
the amino acid incubations on luciferase expression from the NF-κB promoter re-
porter construct are shown in Figure 6.2. The addition of glutamine reduced IL-1β 
induced luciferase expression to 75%, 76%, and 66% of control at 2, 5, and 10 mM, 
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respectively (P<0.001). Luciferase expression was decreased to 89%, 87%, and 78% 
by 2, 5, and 10 mM of leucine and to 83%, 71%, and 57% by 2, 5, and 10 mM of pro-
line (all P<0.001). Incubation with glucose had no effect on NF-κB promoter driven 
luciferase expression (96% (P=0.395), 98% (P=0.706), and 92% (P=0.133) at 2, 5, and 
10 mM, respectively). 
 
 
 
Figure 6.1. Effect of amino acids on IL-8 production in HepG2 cells. Cells were treated with IL-1β (5 
ng/mL) and the amino acids glutamine, leucine and proline for 24 h. Values are presented as means ± 
SD (n=6).  
*Statistically different from control (P<0.05). 
 
 
 
Figure 6.2. Effect of amino acids on NFκB activity, as measured using a NF-κB promoter driven 
luciferase construct, in HepG2 cells after stimulation with IL-1β (5 ng/mL) for 3 h. Values are expressed 
as percentage of control and are presented as means ± SD (n=12). 
*Statistically different from control (P<0.05). 
 
Effect of amino acids on Akt phosphorylation and GSK-3β phosphorylation 
Glutamine pre-incubation for 24 h increased basal Akt phosphorylation at 25 mM 
(Figure 6.3a). In cells treated with both TNF-α and glutamine, Akt phosphorylation 
was higher than in cells treated with TNF-α alone, but lower than in cells treated 
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with only glutamine. Pre-incubation with leucine and proline did not change basal 
Akt phosphorylation (Figure 6.3b and 6.3c).  
 As expected, insulin treatment (1 nM) for 5 min increased Akt phosphorylation. 
Pre-incubation with TNF-α for 24 h reduced insulin-stimulated phosphorylation of 
Akt. All three amino acids were able to (partly) restore the TNF-α-decreased Akt 
phosphorylation to the level of Akt phosphorylation in the insulin-stimulated condi-
tion without TNF-α. The addition of glucose had no effect on Akt phosphorylation in 
the absence or presence of insulin and TNF-α. 
 Levels of phosphorylated GSK-3β were not changed after insulin stimulation, 
nor were they affected by amino acid treatment. 
Discussion 
In this study, we showed that the amino acids glutamine, leucine and proline may 
reduce IL-1β stimulated inflammation, probably through inhibition of NF-κB, and 
that they might be able to modulate insulin signalling in the HepG2 liver cell model. 
 To investigate the effects of these amino acids on inflammation, we studied the 
production of interleukin 8. IL-8 is a major pro-inflammatory cytokine, which main 
function is the attraction of leukocytes to the site of infection. IL-8 and other cyto-
kines, such as IL-1, IL-6 and TNF-α, have been found to be elevated in obese sub-
jects [208-210]. In NAFLD patients, circulating levels of IL-8 were increased and cor-
related with TNF-α and IL-6 concentrations [211]. Moreover, IL-8 has been associ-
ated with the development of atherosclerosis and cardiovascular disease [212]. Adi-
pose tissue is partly responsible for the increased production of these cytokines, but 
another part of this cytokine production originates from an increased inflammatory 
response of the liver. We showed that simultaneous incubation of HepG2 cells with 
amino acids and IL-1β attenuates the production of IL-8 induced by IL-1β.  These ob-
servations are in agreement with experiments in human intestinal cells, in which 
several amino acids have also been described to decrease IL-8 production under 
basal conditions and after stimulation with cytokine mixtures or hydrogen peroxide 
[195, 198]. Here we show this inflammation attenuating effect for the first time, to 
our knowledge, in a liver cell model. 
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Figure 6.3. Representative image of the effects of amino acids on Akt phosphorylation in HepG2 cells. 
Cells were pre-treated with glutamine (A), leucine (B), or proline (C) in absence or presence of TNF-α (10 
ng/mL) for 24 h. Cells were then stimulated with insulin (1 nM) for 5 min. 
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The production of many pro-inflammatory cytokines, including IL-8, is mainly under 
control of the transcription factor Nuclear Factor κB (NF-κB) [213]. Following a pro-
inflammatory stimulus, a signalling cascade is initiated resulting in the translocation 
of NF-κB into the nucleus, where it regulates the transcription of its target genes. In 
our experiments, we found that glutamine, leucine, and proline are all able to signif-
icantly reduce the activity of NF-κB induced by IL-1β, as measured using a luciferase 
expression construct driven by the NF-κB promoter. Our results therefore suggest 
that the inhibition of IL-8 production by these amino acids is mediated through the 
inhibition of NF-κB transcriptional activity. Hubert-Buron et al. [197], who found a 
reduction in IL-8 production in human intestinal epithelial cells after glutamine pre-
treatment, reported a concomitant decrease in ubiquitination of IκBα, the cellular 
inhibitor of NF-κB. This suggests that amino acids may reduce cytokine production 
by limiting IκB ubiquitination. However, the exact mechanism behind these effects 
remains to be unravelled. In summary, our results suggest that it might be of inter-
est to further explore the physiological effects of amino acids and proteins on in-
flammatory markers. 
 Furthermore, we studied the effects of amino acids on insulin signalling. Hereto 
the cells were incubated with TNF-α to induce a state of insulin resistance, as TNF-α 
has been shown to downregulate IRS-1 and subsequently inhibit the insulin signal-
ling cascade in HepG2 cells [214]. In our experiments, TNF-α indeed reduced insulin 
stimulated Akt phosphorylation. Addition of glutamine partly abolished this TNF-α 
induced inhibition. Leucine and proline showed similar effects. These results may 
imply that these amino acids could (partly) diminish the insulin resistant state in-
duced by TNF-α. This could be an important observation for the prevention of me-
tabolic diseases, as these often involve elevated plasma levels of this cytokine. Inte-
restingly, we also observed an increase in Akt phosphorylation after incubation with 
glutamine alone, without insulin, but not after incubation with leucine or proline 
only. Amino acids have been shown to downregulate IRS-1, but to upregulate GLUT-
4 in rat heart tissue [201]. The authors hypothesized that although the expression of 
IRS-1, the direct downstream substrate of insulin, is reduced, amino acids may sti-
mulate glucose transport and overcome insulin resistance by inducing the expres-
sion of GLUT-4 via other routes. However, no data on phosphorylation of IRS-1 or 
translocation of GLUT-4 were reported and physiological effects are therefore spe-
culative. Our observations also imply that these nutrients may play a role in mod-
ulating the insulin signalling pathway and they therefore might be a useful nutrient 
to consider in the treatment of insulin resistance. Indeed, a high-protein diet may 
be helpful in controlling blood glucose in type 2 diabetic patients [215]. However, 
Akt is part of a very complex signalling pathway involving many molecules, and its 
function may vary from one organ to another. In fact, glucose uptake in the liver, fa-
cilitated by GLUT-2, is an insulin- and Akt-independent event [216]. Glycogen syn-
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thesis is a more downstream event in the liver that is dependent on insulin and Akt. 
Therefore, we also determined the effects of amino acids on levels of phosphory-
lated GSK-3β, the key enzyme in glycogen synthesis. However, we were not able to 
detect any differences in P-GSK-3β levels after insulin or amino acid treatment. So, 
although Akt phosphorylation is increased by amino acid treatment, the down-
stream effects of this phenomenon are not clear. It has also been proposed that a 
relationship exists between inflammation and insulin resistance. NF-κB is now 
thought to be involved in the development of obesity- and diet-induced insulin re-
sistance, providing the link between inflammation and insulin resistance [217, 218]. 
Our observation that NF-κB activity is reduced by amino acid treatment could there-
fore also have implications for insulin sensitivity. In fact, the increased phosphoryla-
tion of Akt could also be a result of the NF-κB suppression exerted by the amino ac-
ids. The exact mechanism, as well as the in vivo effects, however, remains to be fur-
ther investigated. 
 Taken together, our results indicate that the amino acids glutamine, leucine and 
proline reduce the production of IL-8 in HepG2 cells, probably by inhibiting NF-κB 
activity. We also found that these amino acids were able to restore the phosphory-
lation of Akt after TNF-α treatment, but the physiological consequences of these ef-
fects remain to be elucidated. Therefore, further research is necessary to explore 
the in vivo effects of these amino acids and their possible role in the treatment of 
metabolic diseases. 
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Introduction 
The combination of the metabolic aberrations related to the metabolic syndrome, a 
growing health problem worldwide, dramatically enhances the risk to develop di-
abetes and cardiovascular disease, still the leading cause of death in the western 
world. Dietary changes are important for its prevention and a special role has been 
suggested for dairy products, since several epidemiological studies have found a 
negative relation between dairy consumption and the metabolic syndrome and its 
different components. In the studies described in this thesis, we therefore aimed to 
increase our understanding into the longer-term and acute effects of dairy con-
sumption on metabolic risk parameters in overweight subjects and the mechanisms 
behind these effects. 
Dairy products: nutrient dense foods 
According to the Dutch Food Consumption Survey, the average daily intake of dairy 
products in the Netherlands is approximately 400 grams [219]. Milk and milk drinks 
comprise the largest part of this daily consumption, followed by yogurt, cheese, and 
desserts. Dairy provides 15% of total energy and 18% of total fat intake. Its contri-
bution to saturated fat intake is 29%, which is an important reason to recommend 
the consumption of reduced-fat dairy products. For total protein consumption, 26% 
is comprised by dairy protein, which is, moreover, of high quality. Milk protein has 
the highest Protein Digestibility Corrected Amino Acid Score (PDCAAS) - a measure 
of protein quality based on human amino acid needs and protein digestibility - leav-
ing proteins from e.g. egg, beef, soy and wheat behind [220]. Further, milk products 
supply 68% of total calcium consumption, as well as substantial amounts of other 
minerals such as magnesium, copper, zinc and selenium. Its contribution to the in-
take of B-vitamins is also significant [219]. So, dairy products are an important 
source for a large variety of essential nutrients. Since they additionally provide rela-
tively little energy, dairy products are considered as nutrient-dense food products.  
 The Netherlands Nutrition Centre (Voedingscentrum) advises adults to consume 
450 mL milk (products) and 30 g cheese per day, mainly to meet the daily require-
ments for calcium (1000-1200 mg for adults). Calcium, in combination with vitamin 
D, and possibly with other nutrients from milk, is needed to obtain and maintain 
good bone health [221, 222]. Further, calcium and dairy consumption are associated 
with a lower risk of colon cancer [223]. In contrast, calcium is thought to increase 
the risk of prostate cancer at high intakes (>2000 mg/d) [224]. Consumption of milk 
and milk products is therefore an easy way to meet the body’s needs for calcium 
and other nutrients. Due to their high nutrient density, low-fat dairy products do – 
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for most people – fit well within a balanced, healthy diet. Some people, however, 
suffer from lactose intolerance; a deficiency in the enzyme lactase that leads to 
maldigestion of lactose and subsequent gastro-intestinal discomfort. While around 
75% of the total world adult population has a decreased ability to digest lactose, on-
ly <5% of the Northern European population is lactose intolerant. However, for 
most people with lactose intolerance, consumption of small amounts of dairy does 
not cause problems [225]. Especially cheese, which contains little lactose, or fer-
mented products such as yogurt, are well tolerated [226]. Cow’s milk allergy, in 
which milk proteins cause an allergic reaction, is another possible problem with 
dairy consumption. This condition is present in only <5% of the European popula-
tion, mainly in toddlers who outgrow the allergy when they get older.  
Long-term effects of dairy intake 
Several cross-sectional and prospective cohort studies have reported a negative cor-
relation between dairy consumption and the development of the metabolic syn-
drome or its components [36-40, 43, 44], whereas others have not [41, 42]. Though 
some studies have evaluated individual products [40, 43], the majority of studies 
have considered dairy products as one food group, mostly including milk, yogurt, 
and cheese [36-39, 44]. The objective of our first trial was to evaluate the longer-
term effects of dairy consumption in an intervention study. Overweight subjects 
were therefore studied for two periods of 8 weeks, in which they either consumed 
low-fat dairy products or control products. In the dairy intervention, subjects con-
sumed 500 mL of low-fat milk and 150 g of low-fat yogurt daily. In the control pe-
riod, they received fruit juice and fruit biscuits, since subjects who do not or hardly 
consume dairy products are likely to use carbohydrate-rich products like these in-
stead. 
Lipid metabolism 
After 8 weeks of low-fat dairy consumption, there were no differences in total and 
LDL-cholesterol, but HDL-cholesterol was decreased by 0.04 mmol/L (chapter 3). 
This decrease was accompanied by a reduction in apoA-1 concentrations of 0.04 g/L 
and a reduction in HDL particle number of 1.07 µmol/L. In a recent trial by Wen-
nersberg et al., middle-aged subjects in Finland, Norway and Sweden with traits of 
the metabolic syndrome consumed 3-5 portions of dairy products daily [150]. Sub-
jects in the control group maintained their habitual diet. Because dairy products did 
not replace other food products, energy intake tended to be higher in the milk 
group, although not statistically significant. After 6 months, a small increase in total 
cholesterol was found, while changes in LDL and HDL-cholesterol were not statisti-
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cally different between the groups. This increase was mainly seen in the Swedish 
group, and a statistically significant raise in apoB concentrations was only observed 
in this group. The Swedish subjects had the largest increase in milk fat intake, be-
cause they consumed higher-fat products than the Norwegian and Finnish partici-
pants. Their saturated fat intake was raised by 13 g (5.5 En%), which was a larger in-
crease than in our intervention (4.7 g or 2.1 En%).  
 In our trial, total fat intake was increased by 3.2 En%, saturated fatty acid intake 
by 2.1 En%, and monounsaturated fatty acid intake by 1.1 En%. It can be estimated 
that these changes, although small, would have caused an increase of 0.07 mmol/L 
in serum total cholesterol, 0.06 mmol/L in LDL-cholesterol, and 0.03 mmol/L in HDL-
cholesterol [117]. Besides fat and fatty acids, other dairy components may also af-
fect the serum lipid profile. Studies on calcium supplementation have mostly shown 
reduced concentrations of total and LDL-cholesterol [49-51, 53]. One study has also 
reported an increased concentration of HDL-cholesterol [49]. However, we did not 
find changes in total and LDL-cholesterol, while HDL-cholesterol even decreased. Ef-
fects of protein, another major dairy constituent, are not consistent. Krauss et al. 
have reported increased concentrations of LDL- and HDL-cholesterol [78], whereas 
Appel et al. have found decreased concentrations of these parameters when a high-
protein diet was compared with a high-carbohydrate diet [80]. Both investigators, 
however, observed a reduced total to HDL-cholesterol ratio when protein intake 
was increased. Our observation that HDL-cholesterol was reduced by milk consump-
tion may be a result of the exchange of carbohydrate for protein intake, as sug-
gested by the findings from the OmniHeart trial [80].  
 Further, it has been hypothesized that the matrix of dairy products may influ-
ence the response to single constituents, such as fat [227]. A number of interven-
tion studies showed different effects of fat from different dairy products on serum 
lipid profiles [104-106]. Especially cheese seems to raise LDL-cholesterol less when 
compared with butter. Differences in calcium content could only partly explain the 
results. The different packaging of lipid globules in cheese, milk and butter may also 
be involved, but its influence on fat absorption and metabolism is not yet known. 
Further, there may be a role for fermentation [228]. Bacteria from fermented prod-
ucts can convert carbohydrates into short chain fatty acids (SCFA) in the colon. An 
altered intestinal SCFA composition may be reflected in serum SCFA patterns, which 
might alter cholesterol synthesis [229, 230]. However, the role of SCFA in cholester-
ol synthesis and the role of fermented dairy products on serum SCFA concentrations 
are uncertain. In our study, we used milk and yogurt and the effects of fermentation 
may thus apply in part of our products. Our results might have been slightly differ-
ent when other dairy products, e.g. cheese, would have been used, if matrix effects 
do play a part. Taken these possible effects of the matrix into account, it seems im-
portant to study products or meals in addition to single nutrients. While studies on 
single components contribute to a better mechanistic understanding than studies 
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on products, the latter provides more information on the physiological effects in the 
everyday situation.  
Glucose metabolism 
We observed no effects of dairy consumption on fasting glucose or insulin concen-
trations (chapter 3). The use of fasting concentrations as markers of glucose meta-
bolism and insulin sensitivity is sometimes questioned, since postprandial hypergly-
cemia is thought to be particularly harmful and may occur before the increase in 
fasting glucose concentrations is present [231]. Nevertheless, impaired fasting glu-
cose (IFG) and impaired glucose tolerance (IGT) often occur together and fasting 
hyperglycemia predicts postprandial glucose excursions [162]. To obtain detailed in-
formation on glucose profiles throughout the day, we also measured glucose con-
centrations by a continuous glucose monitoring system (CGMS) in a subgroup of 12 
subjects. A glucose sensor, inserted into the subcutaneous adipose tissue of the ab-
dominal region, measured glucose concentrations every 5 min during two days in 
the last week of each experimental period. From these data, iAUC above several cut 
off points were calculated during 48 hours. However, the use of these CGMS devices 
did not reveal any effects of dairy consumption on daylong glucose profiles.  
 In our in vitro experiments described in chapter 6, we showed that the addition 
of glutamine, leucine, and proline – the amino acids most abundantly present in 
dairy products – to the culture media of HepG2 liver cells may restore the phospho-
rylation of Akt after TNF-α treatment. Increased concentrations of inflammatory cy-
tokines have been associated with obesity and the metabolic syndrome, and TNF-α 
have been shown to induce insulin resistance in these liver cells. In these conditions, 
amino acids might therefore overcome the TNF-α induced insulin resistance by res-
cuing P-Akt in the liver. Postprandial effects of several amino acids on glucose and 
insulin concentrations have been studied in vivo. Lysine [188], proline [189], glycine 
[190] and arginine [191] reduced glucose concentrations without affecting insulin, 
whereas leucine [192] and phenylalanine [193] caused a decrease in glucose and a 
concomitant decrease in insulin concentrations. In the longer term, a high-protein 
diet was helpful in controlling blood glucose concentrations in type 2 diabetic sub-
jects [215]. However, more information on the longer-term in vivo effects of specific 
amino acids on glucose and insulin metabolism is needed.   
Inflammation 
After 8 weeks of dairy consumption, we observed a significant increase in s-TNFR-2, 
and a trend towards increased s-TNFR-1 and decreased TNF-α concentrations 
(chapter 4). Although the role of soluble TNF-α receptors is not fully understood, it 
has been postulated that they bind TNF-α to inhibit its function. Together with the 
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reduction in TNF-α concentrations, the increase in these receptors may imply an 
overall suppression of the TNF-α pathway. However, the physiological effects re-
quire further study. Other markers of inflammation and endothelial dysfunction, 
such as MCP-1, IL-6, s-ICAM, and s-VCAM, were unaffected by dairy consumption. 
Wennersberg et al. found no effects on inflammatory (IL-6, TNF-α, CRP) and endo-
thelial markers (E-selectin, VCAM-1, vWF) after 6 months of dairy intake [150]. In 
contrast, Zemel et al. observed reductions in TNF-α and IL-6 concentrations in mice 
fed a high-dairy diet [111]. In human subjects, increased concentrations of adipo-
nectin and decreased concentrations of CRP were found after 4 weeks of high dairy 
consumption by retrospective analysis of archived samples. However, effects of an 
improved body composition could not be excluded. In a recent trial, the effects of a 
dairy-rich diet on inflammatory stress were compared with those of a soy-
supplemented diet in the absence of adiposity changes [156]. The dairy-
supplemented diet improved the inflammatory profile by suppression of TNF-α, IL-6 
and MCP-1, and induction of adiponectin after 4 weeks. The authors suggested that 
these effects may be due to a suppression of plasma 1,25-(OH)2-D3. In our study, 
plasma concentrations of 1,25-(OH)2-D3 were also reduced by dairy consumption, 
but no effects on inflammatory parameters were found. Another hypothesis is that 
leucine, highly present in dairy, stimulates sirtuin 1 (Sirt1), which in turn suppresses 
NF-κB and thereby attenuates inflammatory stress [156]. Taken together, effects of 
dairy products on inflammatory parameters are controversial and warrant further 
study.  
 In our in vitro experiments, we also found that there may be a role for amino 
acids in modulating inflammatory processes (chapter 6). Glutamine, leucine and 
proline reduced IL-8 production in liver cells. NF-κB activity was also inhibited by the 
addition of these amino acids. Unfortunately, since other cytokines in our experi-
ments were below detection limits, no conclusions on other inflammatory proteins, 
such as IL-6 and TNF-α can be drawn. Nonetheless, IL-8 is strongly associated with 
atherosclerosis and cardiovascular diseases, and reducing the production of this cy-
tokine may be an important target to lower cardiovascular risk. However, more re-
search is needed to explore the in vivo effects of amino acid consumption and their 
possible role in regulating inflammatory processes. 
Blood pressure 
The statistically significant effect of 8-week dairy consumption was a 2.9-mmHg re-
duction in systolic blood pressure (chapter 3). This reduction may have implications 
for cardiovascular health, since it could substantially reduce the risk of stroke [232, 
233]. An association between dairy intake and lower blood pressure has been 
shown in numerous observational studies [41, 234-236]. In intervention studies, 
such as the DASH-trial [59], comparing a diet high in fruits, vegetables and dairy 
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products with a diet high in fruit and vegetables alone, comparable effects of dairy 
consumption on blood pressure were observed. Calcium intake has been associated 
with blood pressure reductions and calcium might therefore be an important dairy 
component in blood pressure regulation. A recent meta-analysis showed that cal-
cium supplementation (mean dose 1200 mg/d) reduced systolic BP by 1.9 mmHg 
and diastolic BP by 1.0 mmHg, with larger reductions found in subjects with low ha-
bitual calcium intakes [73]. The reduction in 1,25-(OH)2-D3 following increased cal-
cium intake might be involved in this process [237]. However, the exchange of car-
bohydrates for protein may also have contributed to the antihypertensive effects of 
dairy consumption, since both protein and fat have been reported to lower blood 
pressure when compared with carbohydrates [80]. In addition, it has been hypothe-
sized that bioactive peptides derived from milk proteins may reduce blood pressure 
by inhibiting ACE enzyme activity. However, human studies do currently not provide 
unequivocal evidence that ACE inhibitory proteins from dairy lower blood pressure. 
Conclusions on long-term effects of dairy intake 
The results from our 8-week crossover study show that consumption of low-fat 
dairy products, compared with carbohydrate-rich control products, reduced systolic 
blood pressure. Further, it reduced HDL-cholesterol and apoA-1 concentrations. It 
also affected the TNF-α pathway by increasing s-TNFR-2 concentrations, while we 
observed a trend towards increased s-TNFR-1 and decreased TNF-α concentrations. 
The physiological consequences of these last observations are not clear. Overall, 8 
weeks consumption of 500 mL low-fat milk and 150 g low-fat yogurt per day de-
creased systolic blood pressure, but did not have beneficial effects on other meta-
bolic risk markers in overweight and obese subjects. Whether these effects can be 
translated to other forms of dairy products, to other quantities, or to other popula-
tions remains to be elucidated. 
Acute effects of dairy intake 
Besides the longer-terms effects, we were also interested in the short-term post-
prandial effects of dairy products. Postprandial hyperlipidemia and hyperglycemia 
have been considered as risk factors for CVD. Managing these factors may be an al-
ternative strategy to reduce CVD risk, as people in Western countries are in the 
postprandial state for most of the day. Postprandial hyperlipidemia and hypergly-
cemia are frequently seen in subjects with the metabolic syndrome. In this post-
prandial study, we investigated the effects of the addition of milk to a high-fat meal. 
To elucidate which of the components from milk might be involved in its postpran-
dial effects, we also added milk calcium and milk protein to a high-fat meal. The 
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meals contained approximately 40 g fat. After consumption of this amount of fat, a 
substantial triglyceride response is expected [166], while the meal remains palata-
ble.  
Lipid metabolism 
As described in chapter 5, the addition of milk and protein increased the postpran-
dial TAG iAUC when compared to control, whereas the addition of calcium did not 
change the TAG response. Other studies have shown ambiguous effects of protein 
intake on lipid responses. Casein per se did not modulate the TAG iAUC in healthy 
subjects [173, 178] and type 2 diabetics [177]. However, a reduction and delay in 
the TAG peak was found when casein was added to a high-fat meal [175], whereas 
an elevated TAG peak was observed when egg white protein was ingested with a 
fat-rich meal [179]. When casein was ingested in combination with carbohydrates as 
well as fat, it was found to reduce the TAG response in the chylomicron-rich fraction 
in healthy [173] and diabetic subjects [177]. Both investigators suggested that an in-
creased insulin response might account for the reduction in TAG. We did also ob-
serve an increased insulin response after the milk meal, but this did not lead to a 
decreased TAG response. It should be noted, however, that not only the amount of 
protein used in those trials was substantially higher compared with the meals in our 
study, but also the amount of fat. Further, while dairy calcium was previously found 
to reduce postprandial TAG responses [57], we did not observe such an effect. Al-
though the meals contained large amounts of SFA (mainly C14:0, C16:0, and C18:0), 
which are thought to bind to calcium as described in chapter 2, calcium did not af-
fect serum TAG. 
 Despite the increased insulin response, no differences in FFA concentrations 
were observed. This finding is in line with Brader’s observations in diabetic subjects, 
who also showed an increased insulin response when protein was added to the 
meal, while there were no differences in FFA AUC [177]. Westphal et al., however, 
did find a significant decrease in FFA iAUC after casein consumption and the authors 
postulated that the insulinotropic action of casein is responsible for this effect [173]. 
In their other postprandial trial, FFA responses were suppressed when casein or soy 
protein was added to a high-fat meal [175]. However, insulin concentrations were 
only modestly increased, since the meals did not contain carbohydrates.  
Glucose metabolism 
Although the amount and composition of the protein was similar in the milk and the 
protein meal, the insulin responses were different (chapter 5). The insulin iAUC af-
ter the milk meal was 35% higher when compared to control, whereas the iAUC was 
not different after the protein meal. The protein content and amino acid composi-
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tion of the milk and protein drinks were similar. Also, plasma amino acid analysis re-
vealed that amino acid concentrations after these drinks were comparable, but dif-
ferent from the control and calcium drinks, which does not suggest that the absorp-
tion of amino acids from the milk and protein meal were different. The iAUC for glu-
cose was not affected by protein or milk, but the maximal increases in glucose con-
centrations were decreased by both drinks compared with the control drink. This 
observation might be related to the increased concentrations of amino acids, since 
some amino acids have been found to reduce glucose concentrations even in the 
absence of an elevated insulin response as described earlier. In our in vitro experi-
ments, we did observe a role for glutamine, leucine, and proline in insulin signalling. 
The results from these experiments may suggest that amino acids could restore the 
effects of insulin in a situation of reduced insulin sensitivity. However, the in vivo ef-
fects of amino acids, especially in combination with other nutrients, have to be fur-
ther examined. 
Conclusions on acute effects of dairy intake 
The results of our study on postprandial responses after milk and milk constituent 
intake show that milk and protein increased the postprandial TAG response after a 
high-fat mixed meal. Further, milk and protein ingestion reduced the maximal in-
crease in glucose concentration, which may be related to increases in plasma amino 
acid concentrations. Plasma FFA were unchanged, although insulin concentrations 
were elevated after the milk meal. Calcium did not have effects on postprandial 
responses. So, addition of 500 mL low-fat milk to a mixed meal has ambiguous ef-
fects on postprandial metabolic risk profiles in overweight subjects, as it decreased 
glucose concentrations but increased TAG concentrations. For a more complete pic-
ture, however, other metabolic risk factors, such as inflammatory markers, should 
be taken into account. 
Methodological considerations 
Although observational studies have reported an inverse association between dairy 
intake and the metabolic syndrome, they do not provide evidence for a causal rela-
tionship. Our intervention studies, however, could not confirm the hypotheses 
raised by these epidemiological studies. Metabolic health status is the result of a 
very complex interplay between many factors and the association with nutrition 
may be subtle. Though in epidemiological research many factors were taken into 
account, there may always be some unknown confounders.  
 Overweight subjects often display one or more metabolic disturbances, such as 
insulin resistance, dyslipidemia, chronic low-grade inflammation, or hypertension. 
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They are at increased risk of developing metabolic disorders and eventually the me-
tabolic syndrome. It should be noted that the observed effects may only apply to 
overweight and obese subjects. It is, however, not likely that dairy consumption 
would have had a larger impact on metabolic health in lean subjects. It could be 
speculated that dairy intake above a certain level does not have additional effects. 
Therefore, a low habitual dairy intake (<500 g/d of milk, yogurt plus cheese prod-
ucts) was one of the inclusion criteria so that only subjects with a low habitual dairy 
intake were enrolled in the study. Further, the study duration of 8 weeks should 
have been long enough to establish diet-induced changes in plasma parameters, 
such as lipoproteins [238]. However, if changes in plasma parameters would be a 
consequence of changes in body composition, a period of 8 weeks might have been 
too short to induce such alterations. While fasting concentrations of risk parameters 
were hardly affected by 8 weeks of dairy consumption, it is possible that postpran-
dial responses would have been altered after a period of low-fat dairy intake. On 
the other hand, the results in our postprandial trial might have been different if sub-
jects would have consumed milk or milk constituents for a certain period preceding 
the postprandial tests. To ensure whether longer-term dairy consumption is intert-
wined with postprandial effects, a study combining a long-term dairy intervention 
with a postprandial challenge is recommended.  
 A potential problem with trials in free-living subjects is that study conditions 
cannot be fully controlled. Subjects were carefully instructed not to change their 
habitual diet, use of medication or physical activity during the interventions, but we 
had to rely on the subjects’ self-reported acquiescence. Regarding dietary com-
pliance, a strength of our longer-term study is that 1,25-(OH)2-D3 was used as a 
compliance marker, so that we were not fully dependent on dietary records and 
products returned. Conditions in our postprandial study were easier to control – at 
least during the test days.  
General conclusions 
The results described in this thesis do not fully support the findings from observa-
tional research, which indicated a negative relation between dairy intake and the 
metabolic syndrome. Our first intervention study showed a beneficial reduction in 
systolic blood pressure, but also a reduction in HDL-cholesterol after daily consump-
tion of 500 mL low-fat milk and 150 g low-fat yogurt for 8 weeks. Further, dairy con-
sumption seemed to influence the TNF-α pathway. Our in vitro experiments sug-
gested a beneficial role for amino acids in insulin sensitivity, but this could not be 
concluded from glucose and insulin concentrations in fasting plasma samples from 
our 8-week intervention study. Although our subjects were overweight and obese, 
they were otherwise healthy. It remains therefore to be elucidated to what extent 
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these findings can be extended to less insulin-sensitive subjects. Our acute post-
prandial study did however show that low-fat milk, consumed with a high-fat meal, 
reduced the postprandial rise in plasma glucose. At the same time, however, it in-
creased the insulin and triglyceride response postprandially. The protein fraction of 
the milk seemed to be mainly accountable for these effects. Future studies should 
reveal to what extent these effects can be translated to other forms of dairy prod-
ucts, to other quantities, or to other populations.  
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The metabolic syndrome, a constellation of metabolic disturbances, strongly en-
hances the risk of cardiovascular diseases and type 2 diabetes mellitus. It is charac-
terized by abnormalities in a wide variety of metabolic risk markers, including ab-
dominal obesity, hypertension, atherogenic dyslipidemia, insulin resistance, and a 
prothrombotic and proinflammatory state. Although the aetiology of the metabolic 
syndrome has not been fully established, it is clear that obesity, insulin resistance, 
and environmental factors, such as diet, are major players in its development. Die-
tary changes are important for its prevention and a special role has been suggested 
for dairy products. Numerous observational studies have shown a negative associa-
tion between dairy intake and the metabolic syndrome or its components, but in-
tervention studies on the metabolic effects of dairy consumption are scarce. In 
chapter 2, an overview of literature on the physiological effects of three main dairy 
constituents (calcium, protein, and fat) on components of the metabolic syndrome, 
as well as the possible mechanisms involved, is given. Calcium supplements improve 
the serum lipoprotein profile and reduce blood pressure. Effects of calcium may be 
related to intestinal binding to fatty acids or bile acids, or to changes in intracellular 
calcium metabolism by suppressing calciotropic hormones. Dietary proteins may 
play a role in body weight regulation. Further, dairy proteins are precursors of ACE-
inhibitory peptides, which may lower blood pressure, but such effects have inconsis-
tently been reported in human studies. Finally, CLA, which effectively lowers body 
weight in animals, has no such effect in humans in the quantities provided by dairy 
products. 
 This thesis further describes the results of human intervention studies and in vi-
tro experiments addressing the effects of dairy products or its constituents on sev-
eral metabolic disturbances associated with the metabolic syndrome. In our first tri-
al, described in chapters 3 and 4, we studied the effects of low-fat dairy consump-
tion on metabolic risk parameters in overweight and obese subjects. Thirty-five 
overweight, but otherwise healthy, subjects consumed 500 mL of low-fat milk and 
150 g of low-fat yogurt, or 600 mL of fruit juice and 3 fruit biscuits per day for 8 
weeks, in randomized order. Compared with the control period, the decrease in 
plasma 1,25-dihydroxy vitamin D3 concentrations after the low-fat dairy period 
confirmed dietary compliance. Systolic blood pressure was decreased by 2.9 mmHg 
after dairy consumption compared with control, while the difference in diastolic 
blood pressure did not reach statistical significance. Further, low-fat dairy 
consumption decreased HDL-cholesterol and apoA-1 concentrations. Serum total 
cholesterol, LDL-cholesterol, apoB, TAG, FFA, glucose, insulin, CRP and PAI-1 were 
unchanged. We also investigated the effects of dairy consumption on a range of 
inflammatory markers and adhesion molecules. Dairy consumption affected the 
TNF-α pathway by increasing s-TNFR-2 concentrations, while we observed a trend 
towards increased s-TNFR-1 and decreased TNF-α concentrations. The physiological 
consequences of these last observations are not clear. Overall, we concluded that 8 
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weeks of dairy consumption decreased systolic blood pressure, but did not have 
beneficial effects on other metabolic risk markers in overweight subjects. 
 Besides the longer-term effects, we were also interested in the short-term 
postprandial effects of dairy products. Postprandial hyperlipidemia and 
hyperglycemia have been considered as risk factors for CVD. Managing these factors 
may be an alternative strategy to reduce CVD risk, as people in Western countries 
are in the postprandial state for most of the day. Postprandial hyperlipidemia and 
hyperglycemia are frequently seen in subjects with the metabolic syndrome. In this 
postprandial study, we investigated the effects of the addition of milk, and the milk 
constituents protein and calcium, to a high-fat meal, which is described in chapter 
5. Sixteen overweight, but otherwise healthy, subjects participated in 4 postprandial 
tests, in which they consumed a high-fat breakfast and 500 mL of a control, calcium, 
protein or milk drink. The results of this study showed that milk and protein 
increased the postprandial TAG response after a high-fat mixed meal. Further, milk 
and protein ingestion reduced the maximal increase in glucose concentration. 
Plasma FFA were unchanged, although insulin concentrations were elevated after 
the milk meal. Calcium did not have effects on postprandial responses. So, addition 
of low-fat milk to a mixed meal has ambiguous effects on postprandial metabolic 
risk profiles in overweight subjects, as it decreased glucose concentrations but 
increased TAG concentrations. 
 In our in vitro experiments, described in chapter 6, we investigated the effects 
of the amino acids glutamine, leucine and proline on inflammation and insulin sensi-
tivity in HepG2 liver cells. Cells were treated with IL-1β to induce an inflammatory 
response. Incubation with amino acids reduced the production of the pro-
inflammatory cytokine IL-8 and the activity of the transcription factor NF-κB. To 
study the effects of amino acids on insulin sensitivity, cells were incubated with 
TNF-α to induce a situation of insulin resistance. The phosphorylation of Akt, which 
is induced by insulin stimulation, was inhibited by TNF-α treatment. However, 
addition of glutamine, leucine, or proline to the culture media restored Akt 
phosphorylation in the situation of decreased insulin sensitivity. Although these re-
sults seem promising, further research is needed to explore the role of amino acids 
on inflammatory processes and insulin signaling in the in vivo situation. 
 Taken together, the results presented in this thesis do not fully explain the find-
ings from observational research, which indicated a negative relation between dairy 
intake and the metabolic syndrome. Our first intervention study showed a beneficial 
reduction in systolic blood pressure, but also a reduction in HDL-cholesterol after 
daily consumption of 500 mL low-fat milk and 150 g low-fat yogurt for 8 weeks. 
Further, dairy consumption seemed to influence the TNF-α pathway. Our in vitro 
experiments suggested a beneficial role for amino acids in insulin sensitivity, but this 
could not be concluded from glucose and insulin concentrations in fasting plasma 
samples from our 8-week intervention study. Our acute postprandial study did 
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however show that low-fat milk, consumed with a high-fat meal, reduced the 
postprandial rise in plasma glucose. At the same time, however, it increased the 
insulin and triglyceride response postprandially. The protein fraction of the milk 
seemed to be mainly accountable for these effects. Future studies should reveal to 
what extent the observed effects can be translated to other forms of dairy products, 
to other quantities, or to other populations.  
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Het metabool syndroom, een combinatie van verschillende metabole stoornissen, 
verhoogt het risico op hart- en vaatziekten en type 2 diabetes. Het wordt geken-
merkt door diverse metabole risicofactoren, zoals abdominale obesitas, hyperten-
sie, atherogene dyslipidemie, insulineresistentie, chronische inflammatie, en een 
verhoogde stollingsneiging. Hoewel de exacte oorzaak van het metabool syndroom 
onbekend is, is het wel duidelijk dat overgewicht, insulineresistentie en omgevings-
factoren zoals voeding, een belangrijke rol spelen bij het onstaan ervan. Gezonde 
eetgewoonten zijn belangrijk bij het voorkomen van het metabool syndroom en een 
speciale rol lijkt te zijn weggelegd voor zuivelproducten. Verschillende observatione-
le studies hebben aangetoond dat er een negatieve relatie bestaat tussen zuivelcon-
sumptie en (kenmerken van) het metabool syndroom. Interventiestudies op dit ge-
bied zijn er echter nauwelijks.  
In hoofdstuk 2 wordt een overzicht gegeven van studies naar de fysiologische effec-
ten van drie belangrijke zuivelbestanddelen (calcium, eiwit en vet) op kenmerken 
van het metabool syndroom en de mogelijke achterliggende mechanismen. Calci-
umsupplementen verbeteren het serum lipoproteïnenprofiel en verlagen de bloed-
druk. De effecten van calcium zouden te maken kunnen hebben met de binding van 
vetzuren of galzouten in de darm, of met het onderdrukken van de werking van cal-
ciotrope hormonen. Eiwitten in de voeding lijken een rol te spelen in de regulatie 
van lichaamsgewicht. Verder hebben peptiden gevormd uit melkeiwitten een rem-
mende werking op ACE, maar effecten op de bloeddruk zijn nog niet eenduidig aan-
getoond in mensen. Geconjugeerd linolzuur (CLA), tenslotte, verlaagt het lichaams-
gewicht in proefdieren, maar in de hoeveelheden aanwezig in zuivelproducten lijkt 
het geen effect te hebben bij mensen.  
 Dit proefschrift beschrijft verder de resultaten van humaan interventieonder-
zoek en in vitro experimenten naar de effecten van zuivelproducten en -bestand-
delen op verschillende metabole risicofactoren die geassocieerd zijn met het meta-
bool syndroom. In onze eerste interventiestudie, beschreven in hoofdstuk 3 en 4, 
hebben we de effecten van zuivelconsumptie op metabole risicoparameters bestu-
deerd bij mensen met overgewicht. Vijfendertig gezonde proefpersonen met over-
gewicht consumeerden in willekeurige volgorde 8 weken lang dagelijks 500 ml half-
volle melk en 150 g halfvolle yoghurt, of 600 ml vruchtensap en 3 vruchtenbiscuits. 
De plasma concentratie van 1,25-dihydroxy vitamine D3 was lager na de zuivelperi-
ode dan na de controleperiode, hetgeen laat zien dat de deelnemers de experimen-
tele producten hebben gebruikt. De systolische bloeddruk daalde met 2.9 mmHg na 
zuivelconsumptie, terwijl de diastolische bloeddruk niet significant veranderde. 
Verder verlaagde zuivelconsumptie de concentratie van HDL-cholesterol en apoA-1. 
Er waren geen verschillen in totaal cholesterol, LDL-cholesterol, apoB, triglyceriden, 
vrije vetzuren, glucose, insuline, CRP en PAI-1. We hebben ook de effecten van zui-
vel op een aantal inflammatoire eiwitten en adhesiemoleculen bestudeerd. Zuivel-
consumptie beïnvloedde de TNF-α pathway door verhoging van de s-TNFR-2 con-
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centratie. Ook was er een trend tot verhoogde s-TNFR-1 en verlaagde TNF-α con-
centraties. De fysiologische gevolgen van deze veranderingen zijn niet helemaal 
duidelijk. Uit deze resultaten kunnen we echter concluderen dat de consumptie van 
zuivelproducten de systolische bloeddruk verlaagt, maar dat het verder geen gun-
stige effecten heeft op andere metabole risicofactoren bij mensen met overgewicht.  
 Naast de langetermijneffecten, waren we ook geïnteresseerd in de postprandia-
le effecten van zuivelproducten. Postprandiale hyperlipidemie en hyperglycemie zijn 
namelijk ook risicofactoren voor hart- en vaatziekten en tegenwoordig bevinden 
mensen in de Westerse wereld zich gedurende het grootste gedeelte van de dag in 
de postprandiale fase. Postprandiale hyperlipidemie en hyperglycemie komen vaak 
voor bij mensen met het metabool syndroom. In onze postprandiaalstudie hebben 
we gekeken naar de effecten van het toevoegen van melk en de melkbestanddelen 
calcium en eiwit aan een vetrijke maaltijd (hoofdstuk 5). Zestien gezonde proefper-
sonen met overgewicht ondergingen 4 postprandiaaltesten, waarin ze een vetrijk 
ontbijt consumeerden en 500 ml van een controle-, calcium-, eiwit-, of melkdrank. 
Uit de resultaten blijkt dat melk en eiwit de triglyceridenrespons na de vetrijke 
maaltijd verhoogden. Verder verlaagden melk en eiwit de maximale stijging in glu-
coseconcentratie. De respons in vrije vetzuren was niet verschillende tussen de in-
terventies, terijl de insulinerespons verhoogd was na de melk-maaltijd. Calcium had 
geen effect op de postprandiale responsen. We concluderen hieruit dat het toevoe-
gen van melk aan een vetrijke maaltijd tegengestelde effecten heeft op het post-
prandiale risicoprofiel, omdat het triglycerideconcentraties verhoogt en glucosecon-
centraties verlaagt.  
 In hoofdstuk 6 zijn de in vitro experimenten beschreven, waarin we hebben ge-
keken naar de effecten van de aminozuren glutamine, leucine en proline op inflam-
matie en insulinegevoeligheid in HepG2 levercellen. De cellen werden behandeld 
met IL-1β om een inflammatoire respons op gang te brengen. Het incuberen van de 
cellen met aminozuren verminderde de productie van het proinflammatoire cytoki-
ne IL-8 en de activiteit van de transcriptiefactor NF-κB. Om de invloed van aminozu-
ren op insulinegevoeligheid te bestuderen, werden de cellen eerst geïncubeerd met 
TNF-α. Hierdoor werden de cellen insulineresistent en werd de fosforylering van 
Akt, door insuline, geremd. Wanneer we echter aminozuren aan het medium toe-
voegden, werd de fosforylering van Akt hersteld. Deze resultaten lijken veelbelo-
vend, maar er is verder onderzoek nodig om te bepalen wat de invloed van amino-
zuren op inflammatie en insulinegevoeligheid is in de in vivo situatie. 
 De resulten van de studies beschreven in dit proefschrift kunnen de bevindin-
gen van observationeel onderzoek, die een negatieve relatie tussen zuivelconsump-
tie en het metabool synroom lieten zien, niet geheel bevestigen. Onze eerste inter-
ventiestudie liet zien dat het 8 weken lang consumeren van  500 ml melk en 150 g 
yogurt per dag de systolische bloeddruk verlaagde, maar dat het tevens het HDL-
cholesterol reduceerde. Verder lijkt zuivelconsumptie een effect te hebben op de 
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TNF-α pathway. Onze celexperimenten gaven indicaties voor gunstige effecten van 
aminozuren op insulinegevoeligheid, maar dit bleek niet uit de nuchtere glucose- en 
insulineconcentraties in onze interventiestudie. Uit de resultaten van onze post-
prandiaalstudie bleek wel dat het toevoegen van melk aan een vetrijke maaltijd de 
stijging in plasma glucosewaarden vermindert. Tegelijkertijd verhoogde melk de 
triglyceriden- en insulineresponse. Het eiwit uit de melk lijkt hier grotendeels ver-
antwoordelijk voor te zijn. Verder onderzoek moet aantonen of deze resultaten ook 
gelden voor andere zuivelproducten, andere hoeveelheden, of andere populaties. 
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